



PCT/GB 2004 / 0 0 5 0 5 7



INVESTOR IN PEOPLE

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office  
Concept House  
Cardiff Road  
Newport

South Wales  
NP10 8QQ  
REC'D 07 JAN 2005

WIPO


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 23 December 2004

**BEST AVAILABLE COPY**



GB0303 EB57611-1 D00192  
P01/7700 0.00-0328275.3

# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
South Wales  
NP10 8QQ

1. Your reference N.89652 GCW

2. Patent application number (The Patent Office will fill this part in) 0328275.3 5 DEC 2003

3. Full name, address and postcode of the or of each applicant (underline all surnames) Oxagen Limited  
3 Worcester Street  
Oxford, OX1 2PZ  
UK

Patents ADP number (if you know it) 4509490001  
If the applicant is a corporate body, give the country/state of its incorporation GB

4. Title of the invention LIGANDS

5. Name of your agent (if you have one) J. A. KEMP & CO.  
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode) 14 South Square  
Gray's Inn  
London  
WC1R 5JJ

Patents ADP number (if you know it) 26501

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months. Country Priority application number (if you know it) Date of filing (day / month / year)

7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f) Number of earlier UK application Date of filing (day / month / year)

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request? Yes  
Answer YES if:  
a) any applicant named in part 3 is not an inventor, or  
b) there is an inventor who is not named as an applicant, or  
c) any named applicant is a corporate body.  
Otherwise answer NO (See note d)

## Patents Form 1/77

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form

|             |                 |
|-------------|-----------------|
| Description | 50              |
| Claim(s)    | 6               |
| Abstract    | 1               |
| Drawing(s)  | 3 + 3 <i>ch</i> |

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for a preliminary examination and search (Patents Form 9/77) 1

Request for a substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature(s)

*J.A. Kemp & Co.*  
J.A. KEMP & CO.

Date 5 December 2003

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

WOODS, Geoffrey Corlett  
020 7405 3292

### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered YES in part 8, a Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

# LIGAND

## Field of the Invention

The present invention relates to an endogenous ligand for an orphan G protein coupled receptor and to associated methods, uses, agents, compositions and kits.

## Background to the Invention

Chemokines acting through their cognate receptors are critical for the recruitment of effector immune cells to inflamed tissues, and are therefore of considerable interest as potential targets for the treatment of inflammatory disease. CCRL2 (also known as HCR, CRAM-A and CRAM-B) encodes an orphan chemokine receptor-like protein, which is predicted to be a seven transmembrane protein. G protein coupled receptors (GPCRs) are a family of approximately 500 proteins with a 7 transmembrane structure that transduce cellular signals of a variety of biological mediators. The interaction of a GPCR and its ligand causes a conformational change in the protein and facilitates the binding of small associated heterotrimeric G proteins to the intracellular receptor domains, which initiate a signalling cascade. GPCRs are cell surface receptors and therefore are attractive targets for pharmacological intervention. CCRL2 is expressed at high levels in primary neutrophils and primary monocytes, and is further upregulated on neutrophil activation and when monocytes differentiate to macrophages. However, the importance of CCRL2 in human inflammatory disease has not been investigated.

## Summary of the Invention

The present inventors have identified macrophage inflammatory protein-4 (MIP-4; also known as DC-CK1, CCL18 and PARC) as an endogenous ligand for CCRL2.

Accordingly, the present invention provides a method of detecting an agent that modulates the activity of CCRL2, the method comprising:

- (a) contacting a CCRL2 polypeptide with a macrophage inflammatory protein-4 (MIP-4) polypeptide in the presence of a candidate agent under conditions, which in the absence of the test agent, permit the binding of the MIP-4 polypeptide

to the CCRL2 polypeptide; and

(b) determining whether the candidate agent is capable of modulating the interaction between said CCRL2 polypeptide and said MIP-4 polypeptide.

The present invention further provides:

- 5           - an agent detected by a method of the invention;
- a method of modulating the activating of a CCRL2 polypeptide in a cell, the method comprising delivering an agent according to the invention to the cell;
- a pharmaceutical composition comprising an agent according to the invention and a pharmaceutically acceptable carrier or diluent;
- 10          - a method for treating an inflammatory disease or disorder in an individual, the method comprising administering a therapeutically effective amount of an agent according to the invention or a pharmaceutical composition according to the invention to the individual;
- 15          - an agent according to the invention or a pharmaceutical composition according to the invention for use in a method of treatment of a human or animal body or therapy;
- use of an agent according to the invention in the manufacture of a medicament for the treatment of an inflammatory disease or disorder;
- 20          - a method of activating a CCRL2 signalling pathway in a cell, the method comprising delivering, to the cell, a polypeptide comprising:
  - (a) the MIP-4 sequence shown in SEQ ID NO: 6; or
  - (b) a sequence at least 50% identical to SEQ ID NO: 6 and which binds to and activates a signalling activity of CCRL2;
- 25          or a fragment of SEQ ID NO: 6 which binds to and activates a signalling activity of CCRL2;
- use of a polypeptide comprising:
  - (a) the MIP-4 sequence shown in SEQ ID NO: 6; or
  - (b) a sequence at least 50% identical to SEQ ID NO: 6 and which binds to and activates a signalling activity of CCRL2; or
  - 30       (c) a fragment of SEQ ID NO: 6 which binds to and activates a signalling activity of CCRL2;

a polynucleotide encoding any of said polypeptides or said fragments or an antibody specific for any of said polypeptides or said fragments; for the manufacture of a medicament for treating a CCRL2-related disease or disorder;

- 5           - use of a polypeptide comprising:
- (a) the CCRL2 sequence shown in SEQ ID NO: 2 or 4; or
  - (b) a sequence which is at least 80% identical to SEQ ID NO: 2 or 4 over its entire length and functionally equivalent to CCRL2; or
  - (c) a fragment of SEQ ID NO: 2 or 4 which is functionally equivalent to
- 10           CCRL2,

a polynucleotide encoding any of said polypeptides, or an antibody which binds to any of said polypeptides; for the manufacture of a medicament for treating a MIP-4-related disease or disorder;

- 15           - a method of diagnosing a CCRL2-related disease or disorder in an individual, the method comprising:
- (a) carrying out an amplification reaction on a sample isolated from the individual using primers specific for a polynucleotide encoding a MIP-4 polypeptide; and
  - (b) determining the presence or absence of a polynucleotide encoding a
- 20           MIP-4 polypeptide in the sample and thereby determining the presence of a CCRL2-related disease or disorder in the individual;
- a method of diagnosing a CCRL2-related disease or disorder in an individual, the method comprising:
- (a) amplifying a polynucleotide encoding a MIP-4 polypeptide, using a
- 25           nucleic acid isolated from the individual; and
- (b) determining whether the polynucleotide comprises a polymorphism associated with a CCRL2 related disease or disorder; and
  - (c) determining on the basis of said comparison whether the
- 30           polynucleotide comprises a polymorphism associated with a CCRL2-related disease or disorder.
- a method of diagnosing a CCRL2-related disease or disorder in an individual, the method comprising:

(a) contacting a sample isolated from the individual comprising a CCRL2 polypeptide with a MIP-4 polypeptide under conditions which permit the binding of the MIP-4 polypeptide to the CCRL2 polypeptide;

(b) measuring the activity of the CCRL2 polypeptide; and

(a) comparing the activity of the CCRL2 polypeptide with a standard, wherein a difference in the activity relative to the standard is indicative of the presence of a CCRL2-related disease or disorder in the individual;

- a kit for detecting an agent that modulates the activity of CCRL2, the kit comprising: (i) a CCRL2 polypeptide or a polynucleotide encoding a CCRL2 polypeptide.

#### **Description of the sequences mentioned herein**

SEQ ID NO: 1 shows the polynucleotide that encodes the long form of human CCRL2 (CRAM-A).

SEQ ID NO: 2 shows the amino acid sequence of the long form of human CCRL2 (CRAM-A).

SEQ ID NO: 3 shows the polynucleotide that encodes the short form of human CCRL2 (CRAM-B).

SEQ ID NO: 4 shows the amino acid sequence of the short form of human CCRL2 (CRAM-B).

SEQ ID NO: 5 shows the polynucleotide that encodes human MIP-4.

SEQ ID NO: 6 shows the amino acid sequence of human MIP-4.

#### **Brief Description of the Drawings**

Figure 1 shows LacZ activity in G-protein transplant yeast cells in the presence and absence of MIP-4. LacZ activity is expressed per  $10^6$  cells.

Figure 2 shows the LacZ activity in Gi3 transplant yeast cells at varying concentrations of MIP-4. LacZ activity is expressed per  $10^6$  cells.

Figure 3 shows the LacZ activity in the G-protein transplant yeast cells expressing the Corticotrophin Releasing Factor Receptor (CRFR). LacZ activity is expressed per  $10^6$  cells.

Figure 4 is a flow diagram setting out the steps of a computed-implemented method of diagnosing a CCRL2-related disease or disorder in an individual.

Figure 5 is a flow diagram setting out the steps of a computed-implemented method of diagnosing a MIP-4-related disease or disorder in an individual.

#### Detailed Description of the Invention

5 It is to be understood that different applications of the disclosed methods may be tailored to the specific needs in the art. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting.

10 In addition as used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "a polypeptide" includes a mixture of two or more such polypeptides, reference to "a cell" includes two or more such cells, and the like.

15 All publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety.

#### *Screening for agents that modulate the activity of CCRL2*

20 The invention provides a method of detecting a candidate agent that modulates the activity of CCRL2. The term "modulate" includes any of the ways mentioned herein in which the agent of the invention is able to modulate CCRL2. This includes upregulation or downregulation of CCRL2 expression, upregulation or downregulation of CCRL2 degradation, stimulation or inhibition of CCRL2 receptor activity, including potentiation of CCRL2 activity in response to a MIP-4 polypeptide. The ability of a candidate agent to modulate the activity or expression  
25 of CCRL2 may be determined by contacting a CCRL2 polypeptide with the agent under conditions that, in the absence of the candidate agent, permit activity or expression of CCRL2, for example in the presence of a MIP-4 polypeptide, and comparing CCRL2 activity in the presence and absence of the candidate agent. Preferably, the modulation is a correction of aberrant CCRL2 activity or expression.  
30 CCRL2 activity is typically activation of a G-protein mediated signalling pathway. The G-protein may be any G-protein that is coupled to the CCRL2 polypeptide. Preferably the G-protein is Gi3.



The methods of detecting an agent that modulates the activity of a CCRL2 polypeptide may be carried out *in vitro* (inside or outside a cell) or *in vivo*. In one embodiment the methods are carried out in or on a cell, cell culture or cell extract which comprises a CCRL2 polypeptide or expresses a CCRL2 polynucleotide. The cell is preferably one in which the CCRL2 polypeptide is naturally expressed, such as an endothelial cell. Alternatively, the cell may be a cell that is transformed with a CCRL2 polynucleotide and expresses a CCRL2 polypeptide. Suitable cells include transient, or preferably stable higher eukaryotic cell lines, such as mammalian cells or insect cells, lower eukaryotic cells, such as yeast, or prokaryotic cells such as bacterial cells. Particular examples of cell lines include mammalian HEK293T, CHO, HeLa and COS cells. Preferably the cell line selected will be one which is not only stable, but also allows for mature glycosylation of a polypeptide. Expression of a CCRL2 polypeptide may also be achieved in transformed oocytes.

In another embodiment, the methods are carried out in or on a liposome comprising a CCRL2 polypeptide. Methods for the preparation of liposomes are well known in the art (Woodle and Papahadjopoulos, *Methods Enzymol.*, 1989; 171: 193-217).

In a further embodiment, the methods are carried out in or on virus-induced budding membranes comprising a CCRL2 polypeptide. Methods for the preparation of virus-induced budding membranes are well known in the art (for example, Luan et al., *Biochemistry*, 1995; 34(31): 9874-9883). Viruses may be used to induce budding in cells expressing a CCRL2 polypeptide naturally or cells transformed (transfected) with a CCRL2 polynucleotide.

In a further embodiment, the methods are carried out in or on artificial lipid bilayers. Methods for the preparation of artificial lipid bilayers are well known in the art (Sackmann and Tanaka, *Trends Biotechnol.*, 2000; 18: 58-64; and Karlsson and Lofas, *Anal. Biochem.*, 2002; 300: 132-138). A CCRL2 polypeptide may be integrated into the artificial membrane when the membrane is fabricated.

In a yet further embodiment, the methods are carried out in or on a membrane fraction comprising the CCRL2 polypeptide. A membrane fraction is a preparation of cellular lipid membranes in which some, for example at least 5% or 10%, of the non-membrane-associated elements have been removed. Membrane-associated

elements are cellular constituents that are integrated into the lipid membrane or cellular constituents physically associated with a component integrated into the lipid membrane. Methods for the preparation of cellular membrane fractions are well known in the art (for example, Hubbard and Cohn, 1975, J. Cell. Biol., 64: 461-479).

5 A membrane fraction comprising the CCRL2 polypeptide may be prepared from cells expressing a CCRL2 polypeptide naturally or cell transformed (transfected) with a CCRL2 polynucleotide. Alternatively, a CCRL2 polypeptide may be integrated into a membrane preparation by dilution of a detergent solution of the CCRL2 polypeptide (for example, Salamon et al., 1996, Biophys. J., 71: 283-294).

10 The methods for identifying an agent that modulates the activity of a CCRL2 polypeptide are carried out using a candidate agent. The method typically comprises using one or more candidate agents, for example 1, 2, 3, 4, 5, 10, 15, 20 or 30 or more candidate agents. A candidate agent is a candidate compound being evaluated for the ability to modulate the activity of CCRL2 by the methods of the invention.

15 Candidate agents can be natural or synthetic compounds, including, for example, small molecules, compounds contained in extracts of animal, plant, bacterial or fungal cells, as well as conditioned medium from such cells. Suitable candidate agents which may be tested in the above screening methods include antibody agents (for example, monoclonal and polyclonal antibodies, single chain antibodies, 20 chimeric antibodies and CDR-grafted antibodies) or aptamer agents. The antibody agent may have binding affinity for the CCRL2 receptor or for a MIP-4 polypeptide. Furthermore, combinatorial libraries, defined chemical identities, peptide and peptide mimetics, oligonucleotides and natural agent libraries, such as display libraries (e.g. phage display libraries) may also be tested. Oligonucleotide libraries, such as 25 aptamer libraries may be tested.

The candidate agents may be chemical compounds, which are typically derived from synthesis around small molecules which may have any of the properties of the MIP-4 polypeptide.

30 The candidate agent may be derived from or contained in an environmental sample, a natural extract of animal, insect, marine organism, plant, yeast or bacterial cells or tissues, a clinical sample, a synthetic sample, or a conditioned medium from recombinant cells or a fermentation process. The candidate agent may also be

derived from or contained in a tissue sample which comprises a body fluid and/or cells of an individual and may, for example, be obtained using a swab, such as a mouth swab. The candidate agent may be derived from or contained in a blood, urine, saliva, skin, cheek cell or hair root sample.

5         Batches of the candidate agents may be used in an initial screen of, for example, ten candidate agents per reaction, and the candidate agents of batches which show modulation tested individually. Where a batch of agents shows CCRL2 modulatory activity the test agents may be tested in smaller batches or individually to identify the agent having modulatory activity.

10         Preferred candidate agents are polypeptides, antibodies or antigen-binding fragments thereof, lipids, carbohydrates, nucleic acids and chemical compounds.

       The methods of the invention detect agents that modulate the activity of a CCRL2 polypeptide by determining or assaying the effect of a candidate agent on an activity of the CCRL2 polypeptide such as ligand binding, signalling activity or  
15         chemotactic activity. The methods of the invention are carried out under conditions which, in the absence of the candidate agent, permit the binding of a MIP-4 polypeptide to a CCRL2 polypeptide. These conditions are, for example, the temperature, salt concentration, pH and protein concentration under which a MIP-4 polypeptide binds to a CCRL2 polypeptide. Exact binding conditions will vary  
20         depending upon the nature of the assay, for example, whether the assay uses viable cells or only membrane fraction of cells. However, because CCRL2 is a cell surface receptor and MIP-4 polypeptides are secreted polypeptides that interact with the extracellular domain of CCRL2, preferred conditions will generally include physiological salt concentration (approximately 90 mM) and pH (about 7.0 to 8.0).  
25         Temperatures for binding may vary from 4°C to 37°C, but is preferably 4°C. The concentration of reactants in the binding assay will also vary, but will preferably be from about 0.1 pM to about 10 µM.

       In one embodiment of the invention, the effect of the test sample on the binding of the CCRL2 polypeptide to a MIP-4 polypeptide is monitored. Any  
30         suitable binding assay format can be used to monitor binding and detect any effect. The effect may be measured as a decrease in the binding between a MIP-4 polypeptide and a CCRL2 polypeptide. A decrease of at least 10%, at least 20%, at

least 30%, at least 40%, at least 50%, at least 60%, at least 70% or at least 80% in the binding between a MIP-4 polypeptide and a CCRL2 polypeptide measured in any given assay indicates that the candidate agent modulates the activity of CCRL2.

5 Preferred assays for monitoring any candidate agent-induced changes in the binding between a MIP-4 polypeptide and a CCRL2 polypeptide include label displacement, surface plasmon resonance, fluorescence resonance energy transfer, fluorescence quenching, fluorescence polarization and radioligand binding assays.

10 Label displacement involves contacting a CCRL2 polypeptide with a detectably labelled MIP-4 polypeptide in the presence or absence of increasing concentrations of a candidate agent. To calibrate the assay, control competition reactions using increasing concentrations of an unlabelled MIP-4 polypeptide may be carried out. After contact, bound, labelled MIP-4 polypeptide is measured using a method appropriate for the given label (for example scintillation counting, enzyme assay or fluorescence). Preferred labels include radioisotopes such as tritium or  
15 iodine or any other suitable radionucleotide. Candidate agents are considered to bind specifically to a CCRL2 polypeptide if they displace 50% of labelled MIP-4 polypeptide at a concentration of 10 $\mu$ M or less ( $EC_{50}$  is 10 $\mu$ M or less).

20 Surface plasmon resonance measures binding between the two molecules by the change in mass near an immobilized sensor caused by the binding or loss of binding of a MIP-4 polypeptide to a CCRL2 polypeptide immobilized in a membrane on the sensor. The change in mass is measured as resonance units versus time after injection or removal of the ligand or candidate agent and is measured using a Biacore Biosensor (Biacore AB). A CCRL2 polypeptide may be immobilized on a sensor chip in a thin film lipid membrane according to methods described (Salamon et al.,  
25 1996, Biophys J. 71: 283-294). Generally, a candidate agent may be administered to a MIP-4 polypeptide pre-bound to an immobilized CCRL2 polypeptide and displacement of the ligand measured. Alternatively, a MIP-4 polypeptide may be administered to a candidate agent pre-bound to an immobilized CCRL2 polypeptide.

30 Fluorescence resonance energy transfer (FRET) is a quantum mechanical phenomenon that occurs between a fluorescence donor (D) and a fluorescence acceptor (A) in close proximity to each other if the emission spectrum of D overlaps with the excitation spectrum of A. Generally, the MIP-4 polypeptide and the CCRL2

polypeptide are labelled with a complementary pair of donor and acceptor fluorophores. The fluorescence emitted upon excitation of the donor fluorophore will have a different wavelength when the MIP-4 polypeptide and CCRL2 polypeptide are bound than when they are not bound. Quantitation of bound versus unbound polypeptides can be carried out by measurement of emission intensity at each wavelength. Donor:Acceptor pairs of fluorophores with which to label the polypeptides are well known in the art. Preferred fluorophores are Cyan Fluorescent Protein (CFP, Donor) and Yellow Fluorescent Protein (YFP, Acceptor).

Fluorescence quenching involves labelling one molecule of the binding pair (MIP-4 polypeptide and CCRL2 polypeptide) with a fluorophore while labelling the other with a molecule that quenches the fluorescence of the fluorophore when the pair bind. A change in fluorescence upon excitation may be used to measure a change in the binding between the MIP-4 polypeptide and CCRL2. An increase in fluorescence suggests that the binding between the MIP-4 polypeptide and CCRL2 polypeptide is decreased.

Fluorescence polarization measures the polarization of a fluorescently-labelled MIP-4 polypeptide. The fluorescence polarization value for a fluorescently-labelled MIP-4 polypeptide will change, and generally increase, when the ligand binds to a CCRL2 polypeptide. A decrease in the polarization value is typically indicative of a decrease in binding between the MIP-4 polypeptide and CCRL2 polypeptide. Fluorescence polarization is preferable when the candidate agent is a small molecule.

Large scale, high throughput screening of small candidate agents or libraries of such agents may be screened using biosensor assays. ICS biosensors have been described by AMBRI (Australian Membrane Biotechnology Research Institute; <http://www.ambri.com.au/>). The binding of a ligand for CCRL2 to CCRL2 is coupled to the closing of gramicidin-facilitated ion channels in a membrane bilayer of the biosensors. As a result, the biosensor may measure binding between the MIP-4 polypeptide and CCRL2 polypeptide and therefore any changes in binding upon introduction of a candidate agent.

Agents that interfere with or displace binding of a MIP-4 polypeptide from a CCRL2 polypeptide may be agonists, partial agonists, antagonists or inverse agonists

of CCRL2 activity. Functional analysis can be performed on agents identified according to the invention to determine whether they are an agonist, partial agonist, antagonist or inverse agonist. For agonist screening, a CCRL2 polypeptide is contacted with agent and the signalling activity of CCRL2 measured as described below. An agonist or partial agonist will have a maximal activity corresponding to at least 10% of the maximal activity of a MIP-4 polypeptide. The agonist or partial agonist will preferably have 50%, 75%, 100% activity of the MIP-4 polypeptide or 2-fold, 5-fold, 10-fold or more activity than a MIP-4 polypeptide. For antagonist or inverse agonist screening, CCRL2 polypeptides are assayed for signalling activity in the presence of a ligand for CCRL2, such as a MIP-4 polypeptide, with or without a candidate compound. Antagonists or inverse agonists will reduce the level of ligand-stimulated receptor activity by at least 10%, compared to reactions lacking the antagonist or inverse agonist. For inverse agonist screening, constitutive CCRL2 activity is assayed in the presence and absence of a candidate compound. Inverse agonists are compounds that reduce the constitutive activity of the receptor by at least 10%. Constitutive activity of a CCRL2 polypeptide may be achieved by overexpression by placing, for example, placing it under the control of a strong constitutive promoter such as the CMV early promoter. Alternatively, constitutive activity may be achieved by certain mutations of conserved G-protein couple receptor amino acids or amino acid domains (for example, Kjelsberg et al., 1992, J. Biol. Chem. 267:1430-1430; Ren *et al.*, 1993, J. Biol. Chem. 268:16483-16487; and Samama *et al.*, 1993, J. Biol. Chem 268:4625-4636).

In another embodiment of the invention, the effect of a test sample on the signalling activity of a CCRL2 polypeptide is monitored. The signalling activity of CCRL2 is induced by a MIP-4 polypeptide. Any suitable signalling assay format may be used for monitoring signalling activity and detecting any effect. The effect may measured as a change in the MIP-4 polypeptide-induced signalling activity of CCRL2. A change refers to an increase or a decrease in the signalling activity. A change of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or at least 80% in the signalling activity a CCRL2 polypeptide measured in any given assay indicates that the candidate agent modulates the activity of CCRL2.

The signalling activity of a CCLR2 polypeptide may be monitored by measuring the level of activation of a G protein by the CCLR2 polypeptide. The level of activation of a G protein by CCRL2 may be monitored by measuring the turnover of guanosine derivatives, the activity of guanosine triphosphatase (GTPase) or level of downstream second messenger molecules. Guanosine derivatives are involved in the cyclic reaction of activation and inactivation of G proteins include guanosine diphosphate (GDP) and guanosine triphosphate (GTP). Second messenger molecules are generated or caused to alter in concentration by the activation of a G protein. Examples include but are not limited to cyclic adenine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), diacylglycerol (DAG), inositol triphosphate (IP<sub>3</sub>) and intracellular calcium.

Preferred methods of monitoring signalling activity include measuring guanosine nucleotide binding, GTPase activity, adenylate cyclase activity, cAMP, Protein Kinase C activity, phosphatidylinositol breakdown, diacylglycerol, inositol triphosphate, intracellular calcium, MAP kinase activity and reporter gene expression. In all assays, potential non-specific effects of the candidate agent may be excluded by carrying out control assays using cells or membranes that do not comprise a CCRL2 polypeptide.

Preferably, the signalling activity of the CCRL2 polypeptide is monitored by measuring the activity of Gi3.

GTP binds to membrane-associated G proteins upon activation by a receptor such as a CCRL2 polypeptide. CCRL2 signalling activity may therefore be assayed by measuring the binding of GTP to cell membranes containing receptors (Traynor and Nahorski, 1995, Mol. Pharmacol. 47: 848-854). Generally, GTP is labelled with a suitable detectable moiety and measured by an appropriate detection system.

G proteins comprise a GTPase which hydrolyses GTP to form GDP and inactivates the G protein. GTPase activity is therefore a measure of G protein and therefore CCRL2 activity. GTPase activity may be measured by methods common in the art. Generally, the method involves incubating the membranes containing a CCRL2 polypeptide with  $\gamma$ P-GTP. Active GTPase will release the label as inorganic phosphate which may be detected by scintillation counting.

Another preferred method of monitoring signalling activity is measuring

adenylate cyclase activity (Solomon *et al.*, 1974, *Anal. Biochem.* 58: 541-548; and Kenimer & Nirenberg, 1981, *Mol. Pharmacol.* 20: 585-591). The assay may involve the use of labelled cAMP to estimate the activity of the adenylate cyclase enzyme in protein homogenates from cells or membrane comprising a CCRL2 polypeptide.

5       A yet further preferred method of monitoring signalling activity is the measurement of intracellular cAMP. This may be done using a cAMP radioimmunoassay (RIA) or cAMP binding proteins according to methods known in the art (Horton & Baxendale, 1995, *Methods Mol. Biol.* 41: 91-105). Intracellular cAMP may be measured using a number of commercially available kits including the  
10      High Efficiency Fluorescence Polarization-based homogeneous assay (LJL Biosystems and NEN Life Science Products).

Yet further preferred methods of monitoring signalling activity measure receptor induced breakdown of phospholipids (especially phosphatidylinositol) to generate the second messengers DAG and/or IP<sub>3</sub>. Methods of measuring each of  
15      these are well known in the art (for example, *Phospholipid Signaling Protocols*, edited by Ian M. Bird. Totowa, N.J., Humana Press, 1998; and Rudolph *et al.*, 1999, *J. Biol. Chem.* 274: 11824-11831).

A yet further preferred method of monitoring signalling activity measures receptor induced Protein Kinase C (PKC) activity. DAG activates PKC which  
20      phosphorylates many target proteins and ultimately results in the transcription of an array of proto-oncogene transcription factor-encoding genes, including c-fos, c-myc and c-jun, proteases; protease inhibitors, including collagenase type I and plasminogen activator inhibitor; and adhesion molecules, including intracellular adhesion molecule I (ICAM I). The activity of PKC may be measured directly by  
25      measuring phosphorylation of a substrate peptide, Ac-FKKSFKL-NH<sub>2</sub>, which derived from the myristoylated alanine-rich protein kinase C substrate protein (MARCKS) (Kikkawa *et al.*, 1982, *J. Biol. Chem.* 257: 13341-13348). Assays designed to detect increases in gene products induced by PKC can be used to monitor PKC activation and thereby receptor activity. In addition, the activity of a receptor  
30      that activates PKC can be monitored through the use of reporter gene constructs driven by the control sequences of genes activated by PKC activation (see below).

Another preferred method for monitoring signalling activity measures MAP



kinase activity. Several kits are commercially available, including the p38 MAP Kinase assay kit (New England Biolabs (Cat #9820)) and the FlashPlate(TM) MAP Kinase assay (Perkin-Elmer Life Sciences).

Another preferred method for monitoring signalling activity is the measurement of intracellular calcium. Various methods of measuring intracellular calcium are well known in the art (Demaurex et al., Meth. Cell. Biol., 2002; 70: 453-474). Several kits are commercially available for measuring intracellular calcium including the FILPR assay kits (Biocompare, Inc.). One preferred method of measuring intracellular calcium is the aequorin assay. Mitochondrial apoaquorin is a bioluminescent protein that is responsive to intracellular calcium ion release resulting from the activation of GPCRs such as CCRL2 (Stables et al., 1997, Anal. Biochem. 252:115-126; and Detheux *et al.*, 2000, J. Exp. Med., 192 1501-1508). Generally, cells expressing a CCRL2 polypeptide are transfected to coexpress mitochondrial apoaquorin and Gα16. Any compound that activates the CCRL2 polypeptide, such as a MIP-4 polypeptide, will cause intracellular calcium release and result in a light emission that may be measured. A second preferred method of measuring intracellular calcium is the Fura-2 assay (Molecular Probes, Eugene, OR USA).

Other preferred methods of monitoring signalling activity measure changes in the transcription or translation of one or more genes. Generally, assays measure the expression of a reporter gene driven by control sequences, such as promoters and transcription-factor binding sites, responsive to receptor activation. Cells that comprise a CCRL2 polypeptide may be stably transfected with a reporter gene construct containing appropriate control sequences. Assays tend to involve measuring the response of "immediate early" genes which may be rapidly induced, possibly within minutes, of receptor activation. Suitable reporter genes include, but are not limited to, luciferase, CAT, GFP, β-lactamase or β-galactosidase. An example of a control sequence that may be used in a reporter gene assay are those of the c-fos gene. The induction of c-fos expression is extremely rapid, often within minutes, of receptor activation. The c-fos regulatory elements are well known in the art (Verma *et al.*, 1987, Cell 51: 513-514). A further example of a control sequence that may be used in a reporter gene assay are those recognised by CREB (cyclic

AMP responsive element binding protein). Other examples of control sequences that may be used in a reporter gene assay include, but are not limited to, the vasoactive intestinal peptide (VIP) gene promoter (Fink *et al.*, 1988, Proc. Natl. Acad. Sci. 85:6662-6666); the somatostatin gene promoter (Montminy *et al.*, 1986, Proc. Natl. Acad. Sci. 83:6682-6686); the proenkephalin promoter (Comb *et al.*, 1986, Nature 323:353-356); the phosphoenolpyruvate carboxy-kinase (PEPCK) gene promoter (Short *et al.*, 1986, J. Biol. Chem. 261:9721-9726); and transcriptional control elements responsive to the AP-1 transcription factor (Lee *et al.*, 1987, Nature 325:368-372; and Lee *et al.*, 1987, Cell 49: 741-752) or NF- $\kappa$ B activity (Hiscott *et al.*, 1993, Mol. Cell. Biol. 13: 6231-6240). Although for other signalling activity assays, a change of at least 10% in the presence of a candidate agent indicates that it modulates CCRL2, the transcriptional reporter assay requires at least a two-fold increase in signal to indicate the presence of a positive agent. As with other assays, a negative agent is indicated by at a 10% decrease in signal in the reporter gene expression assay.

The ability of a candidate agent identified by a method of the invention to modulate the signalling activity of a CCRL2 polypeptide may be further confirmed or analysed. This functional analysis is described in detail above. This analysis typically involves monitoring of the effect of candidate agent alone on the signalling activity of a CCRL2 polypeptide and comparison with the effect of a MIP-4 polypeptide on the signalling activity of the CCRL2 polypeptide. Any suitable signalling assay format may be used for determining signalling activity and detecting the effect. The effect may be measured as a change in the signalling activity of CCRL2. The agent may be agonist, partial agonist, antagonist or inverse agonist of CCRL2 activity.

Comparisons are made with a MIP-4 polypeptide at its EC<sub>50</sub>. The EC<sub>50</sub> refers to the concentration of ligand at which the signalling activity is 50% of the maximum for the receptor activity measurable using the same assay. In other words, the EC<sub>50</sub> is the concentration of ligand that gives 50% activation, when 100% activation is set at the amount of activity that does not increase with the addition of more ligand. It should be noted that the EC<sub>50</sub> of a ligand will vary with the identity of the ligand, for example, variants of SEQ ID NO: 6 (i.e., those containing insertions, deletions,

substitutions) can have  $EC_{50}$  values higher than, lower than or the same as the parent molecule. Where a sequence differs from a parent sequence, one of skill in the art can determine the  $EC_{50}$  for that variant according to conventional methods. The  $EC_{50}$  of a given ligand is measured by performing an assay for an activity of a fixed amount of a CCRL2 polypeptide in the presence of doses of the ligand that increase at least until the CCRL2 response is saturated or maximal, and then plotting the measured CCRL2 activity versus the concentration of the ligand.

The candidate agent is regarded as an agent that modulates CCRL2 activity if it induces at least 50% of the signalling activity induced by a MIP-4 polypeptide at its  $EC_{50}$ .

In another embodiment of the invention, the effect of a candidate agent or sample on the chemotactic activity of a CCRL2 polypeptide is monitored. The chemotactic activity of CCRL2 is induced by a MIP-4 polypeptide. Any suitable chemotactic assay format may be used for monitoring chemotactic activity and detecting any effect. A chemotactic assay is a measure of cell migration to a stimulus. The effect may be measured as a change in the MIP-4 polypeptide-induced chemotactic activity of CCRL2. A change refers to an increase or a decrease in the signalling activity. A change of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or at least 80% in the chemotactic activity a CCRL2 polypeptide measured in any given assay indicates that the candidate agent modulates the activity of CCRL2.

A cell for use in a chemotactic assay may be any suitable cell expressing CCRL2. The cell may be transformed with a CCRL2 polynucleotide such that it expresses a CCRL2 polypeptide. Preferably the cell is a primary cell such as an endothelial cell which expresses the CCRL2 polypeptide. Suitable host cells include transient, or preferably stable higher eukaryotic cell lines, such as mammalian cells or insect cells, lower eukaryotic cells, such as yeast, or prokaryotic cells such as bacterial cells. Particular examples of cell lines include mammalian HEK293T, CHO, HeLa and COS cells. Preferably the cell line selected will be one which is not only stable, but also allows for mature glycosylation of a polypeptide. Chemotactic activity of a CCRL2 polypeptide may also be measured in transformed oocytes.

Methods of monitoring chemotactic activity are well documented in the art

and kits are available. Suitable kits include, those using ChemoTx plates (Neuroprobe Inc.) or the BD Falcon HTS FluoroBlok 96-Multiwell Insert System (BD Biosciences Discovery Labware). Examples of chemotactic assays are described in the literature (for example, Biber et al., Journal of Leukocyte Biology 2003, 74:243-251; and Zuurman et al.; BCN annual report 1999-2001). The effect of a MIP-4 polypeptide acting on CCRL2 polypeptide can also be detected by changing the shape of the cells described in the literature (for example, Heineman et al., The Journal of Immunology 2003; 170:4752-4758; and Stubbs et al., Journal of Biological Chemistry 2002; 277:26012-26020).

The invention further provides an agent detected by any of the above-described methods and the use of such an agent in method of treatment of the human or animal body by therapy. The agent may be an agonist, partial agonist, antagonist or inverse agonist of CCRL2 activity. The invention further provides the use of an agent detected by any of the methods of the invention in the manufacture of a medicament for use in treatment of an inflammatory disease or disorder. A pharmaceutical composition for treatment of an inflammatory disease or disorder comprising an agent of the invention and a pharmaceutically acceptable carrier or diluent is also provided.

A method of modulating the activity of a CCRL2 polypeptide in a cell is provided by the invention, which method comprises delivering an agent detected according to the invention to the cell, such that the activity of CCRL2 is modulated. The cell may be *in vivo* or *in vitro*. The delivery of the agent is discussed in more detail below.

A method of treating an inflammatory disease or disorder is also provided by the invention, which method comprises administering a therapeutically effective amount of an agent according to the invention to an individual in need thereof.

A method of treating an inflammatory disease or disorder of the invention typically comprises:

- (i) identifying an agent for the prevention or treatment of an inflammatory disease or disorder by a method according to the invention; and
- (ii) administering a therapeutically effective amount of an agent detecting

in (i) to an individual having an inflammatory disease or disorder.

Where CCRL2 activity or expression is reduced in a subject having an inflammatory disease or disorder, an agent for use in the treatment of the inflammatory disease or disorder is preferably an agonist or potentiator of CCRL2 activity or an agent which enhances expression of CCRL2. Where CCRL2 activity or expression is enhanced in a subject having an inflammatory disease or disorder, a therapeutic agent is typically an antagonist of CCRL2 activity or an inhibitor of expression. The agent may bind to a MIP-4 polypeptide that interacts with the CCRL2 receptor to prevent receptor activation, for example the agent may be an antibody to a MIP-4 polypeptide.

Where MIP-4 activity or expression is reduced in a subject having an inflammatory disease or disorder, an agent for use in the treatment of the inflammatory disease or disorder is preferably an agonist or potentiator of MIP-4 activity or an agent which enhances expression of MIP-4. Where MIP-4 activity or expression is enhanced in a subject having an inflammatory disease or disorder, a therapeutic agent is typically an antagonist of MIP-4 activity or an inhibitor of expression. The agent may bind to a CCRL2 polypeptide that interacts with the MIP-4 and prevent receptor activation, for example the agent may be an antibody to a CCRL2 polypeptide.

In all the above embodiments, the inflammatory disease or disorder is preferably chronic obstructive pulmonary disease (COPD), bronchitis, emphysema, an inflammatory bone disorder, psoriasis, inflammatory bowel disease, an inflammatory brain disorder, atherosclerosis, endometriosis, autoimmune deficiency syndrome (AIDS), lupus erythematosus, allograft rejection or allergic inflammation. The inflammatory brain disorder may be multiple sclerosis, or stroke or hemorrhage. The inflammatory bowel disease may be ulcerative colitis or Crohn's disease. The inflammatory bone disorder may be arthritis, including rheumatoid, autoimmune and infectious arthritis. The allergic inflammation may be, for example, asthma or contact dermatitis. The inflammatory disease or disorder may be a CCRL2-related or a MIP-4-related disease or disorder. An inflammatory disease or disorder may be present, or be suspected of being present, in the individual to be treated. The individual is discussed in more detail below.

*Polypeptides and polynucleotides useful in the invention*

CCRL2 polypeptides useful in the invention include both the long form (CRAM-A) and short form (CRAM-B) of the receptor. Therefore CCRL2

5 polypeptides useful in the invention include those having the sequence of SEQ ID NO: 2 or 4. CCRL2 polypeptides useful in the invention also include variant polypeptides having amino acid sequences that are at least 80%, at least 90% or at least 95% identical to SEQ ID NO: 2 or 4 over its entire length that are functionally equivalent to CCRL2. Preferred variant polypeptides include CCRL2 homologues  
10 from other species such as monkey, dog, mouse, rat, guinea pig or zebra fish.

Fragments of SEQ ID NO: 2 or 4 which are functionally equivalent to CCRL2 may also be used. Such fragments may be from 250 to 355 amino acids in length and are preferably at least 275, 300, 310, 320, 330 or 340 amino acids long. Functionally equivalent means that the CCRL2 polypeptide binds to a MIP-4 polypeptide and is  
15 capable of activating a CCRL2-linked signalling pathway. Generally binding of MIP-4 to the CCRL2 polypeptide stimulates a CCRL2 linked signalling pathway.

Typically, the CCRL2 linked signalling pathway involves activation of Gi3.

Typically, the CCRL2 polypeptide, "specifically binds" to a MIP-4 polypeptide. A CCRL2 polypeptide "specifically binds" to a MIP-4 polypeptide when it binds with  
20 preferential affinity to the MIP-4 polypeptide compared to other polypeptides. A variety of protocols for competitive binding are known in the art (discussed further below).

CCRL2 polynucleotides useful in the invention include polynucleotides that encode a CCRL2 polypeptide. CCRL2 polypeptides useful in the invention include  
25 polynucleotides that encode both the long form (CRAM-A) and short form (CRAM-B) of the receptor. The polynucleotide may comprise the sequence of SEQ ID NO: 1 or 3 or a sequence at least 90% or 95% identical to SEQ ID NO: 1 or 3 over its entire length.

MIP-4 polypeptides useful in the invention include polypeptides having the  
30 sequence of SEQ ID NO: 6. MIP-4 polypeptides useful in the invention also include sequences at least 50%, 60%, 70%, 80%, 90% or 95% identical to SEQ ID NO: 6 over its entire length which binds to and activate a signalling activity of a CCRL2

polypeptide. MIP-4 polypeptides also include fragments of any of the above-mentioned MIP-4 polypeptides which bind to and activate a signalling activity of a CCRL2 polypeptide. Fragments preferably retain at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the binding activity and level of signalling activation of SEQ ID NO: 8. MIP-4 polypeptides can comprise additions, insertions, deletions or substitutions of SEQ ID NO: 6 as long as the resulting polypeptide specifically binds to and activates a signalling activity of a CCRL2 polypeptide and preferably retains at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the binding activity and level of signalling activation of SEQ ID NO: 6.

Typically, the MIP-4 polypeptide "specifically binds" to a CCRL2 polypeptide. A MIP-4 polypeptide "specifically binds" to a CCRL2 polypeptide when it binds with preferential affinity to the CCRL2 polypeptide compared with other receptor polypeptides. A variety of protocols for competitive binding are known in the art.

Polynucleotides that encode a MIP-4 polypeptide are also useful in the invention. Polynucleotides useful in the invention include polynucleotides that encode a MIP-4 polypeptide. The polynucleotide may comprise the sequence of SEQ ID NO: 5 or a sequence at least 50%, 60%, 70%, 80%, 90% or 95% identical to SEQ ID NO: 5 over its entire length.

The above mentioned identity may be calculated on the basis of nucleotide or amino acid identity (sometimes referred to as "hard homology").

For example the UWGCG Package provides the BESTFIT program which can be used to calculate homology (for example used on its default settings) (Devereux *et al* (1984) *Nucleic Acids Research* 12, p387-395). The PILEUP and BLAST algorithms can be used to calculate homology or line up sequences (such as identifying equivalent or corresponding sequences (typically on their default settings), for example as described in Altschul S. F. (1993) *J Mol Evol* 36:290-300; Altschul, S, F *et al* (1990) *J Mol Biol* 215:403-10.

A BLAST analysis is preferably used for calculating identity. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of

length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold (Altschul *et al*, supra). These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extensions for the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) *Proc. Natl. Acad. Sci. USA* 89: 10915-10919) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) *Proc. Natl. Acad. Sci. USA* 90: 5873-5787. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two polynucleotide or amino acid sequences would occur by chance. For example, a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

The homologous sequences typically differ by at least 1, 2, 5, 10, 20 or more mutations (which may be substitutions, deletions or insertions of nucleotide or amino acids). These mutations may be measured across any of the regions mentioned above in relation to calculating identity. In the case of proteins the substitutions are preferably conservative substitutions. These are defined according to the following Table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:



|           |                   |         |
|-----------|-------------------|---------|
| ALIPHATIC | Non-polar         | G A P   |
|           |                   | I L V   |
|           | Polar – uncharged | C S T M |
|           |                   | N Q     |
|           | Polar – charged   | D E     |
|           |                   | K R     |
| AROMATIC  |                   | H F W Y |

Any of the polypeptides useful in the invention may be in the form of a dimer. Any of the polypeptides useful in the invention may further be chemically-modified to form a derivative. Derivatives include polypeptides that have lipid extensions or have been glycosylated. Derivatives also include polypeptides that have been detectably labelled. Detectably labelled polypeptides have been labelled with a labelling moiety that can be readily detected. Examples of labelling moieties include, but are not limited to, radioisotopes or radionucleotides, fluorophores such as green fluorescent protein (GFP), electron-dense reagents, quenchers of fluorescence, enzymes, affinity tags and epitope tags. Preferred radioisotopes include tritium and iodine. Affinity tags are labels that confer the ability to specifically bind a reagent onto the labelled molecule. Examples include, but are not limited to, biotin, histidine tags and glutathione-S-transferase (GST). Labels may be detected by, for example, spectroscopic, photochemical, radiochemical, biochemical, immunochemical or chemical methods that are known in the art.

Any of the polypeptides useful in the invention may also comprise additional amino acids or polypeptide sequences. A preferred polypeptide useful in the invention is a MIP-4 polypeptide with an additional methionine residue attached to the amino terminus (Met-MIP-4) or the carboxy terminus. Any of the polypeptides useful in the invention may comprise additional polypeptide sequences such that they form fusion proteins. The additional polypeptide sequences may be fused at the amino terminus, carboxy terminus or both the amino terminus and the carboxy terminus of MIP-4. Examples of fusion partners include, but are not limited to, GST, maltose binding protein, alkaline phosphatases, thiorexin, GFP, histidine tags and

epitope tags (for example, Myc or FLAG). CCRL2 polypeptides may be fused to a GTP-binding protein (G protein).

*Antibodies useful in the invention*

5           The invention also provides the use of an antibody specific for a MIP-4 polypeptide for the treatment of a CCRL2-related disease or disorder. The invention also provides the use of an antibody specific for a CCRL2 polypeptide for the treatment of a MIP-4-related disease or disorder.

10           Antibodies may be raised which bind to a MIP-4 polypeptide or a CCRL2 polypeptide. Antibodies may be raised which bind to both a MIP-4 polypeptide and a CCRL2 polypeptide. Antibodies may be raised against MIP-4 fusion proteins such as Met-MIP-4. Typically, the antibody "specifically binds" or "is specific for" a MIP-4 polypeptide or a CCRL2 polypeptide. The antibody may bind to a glycosylation site on CCRL2. An antibody, or other compound, "specifically binds"  
15           to a polypeptide or is "specific for" a polypeptide when it binds with preferential affinity to the protein for which it is specific compared to other polypeptides, such as chemokine or G-protein receptor. A variety of protocols for competitive binding or immunoradiometric assays to determine the specific binding capability of an antibody are well known in the art (see for example Maddox *et al*, J. Exp. Med. 158,  
20           1211-1226, 1993). Such immunoassays typically involve the formation of complexes between the specific protein and its antibody and the measurement of complex formation.

          For the purposes of this invention, the term "antibody", unless specified to the contrary, includes fragments which bind a polypeptide. Such fragments include  
25           Fv, F(ab') and F(ab')<sub>2</sub> fragments, as well as single chain antibodies. Furthermore, the antibodies and fragment thereof may be chimeric antibodies, CDR-grafted antibodies or humanised antibodies.

          Antibodies can be produced by any suitable method. Means for preparing and characterising antibodies are well known in the art, see for example Harlow and  
30           Lane (1988) "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. For example, an antibody may be produced by raising an antibody in a host animal against the whole polypeptide or a fragment

thereof, for example an antigenic epitope thereof, herein after the "immunogen". The fragment may be any of the fragments mentioned herein (typically at least 10 or at least 15 amino acids long) and comprise a polymorphism (such as any of the polymorphisms mentioned herein).

5 A method for producing a polyclonal antibody comprises immunising a suitable host animal, for example an experimental animal, with the immunogen and isolating immunoglobulins from the animal's serum. The animal may therefore be inoculated with the immunogen, blood subsequently removed from the animal and the IgG fraction purified.

10 A method for producing a monoclonal antibody comprises immortalising cells which produce the desired antibody. Hybridoma cells may be produced by fusing spleen cells from an inoculated experimental animal with tumour cells (Kohler and Milstein (1975) *Nature* 256, 495-497).

15 An immortalized cell producing the desired antibody may be selected by a conventional procedure. The hybridomas may be grown in culture or injected intraperitoneally for formation of ascites fluid or into the blood stream of an allogenic host or immunocompromised host. Human antibody may be prepared by *in vitro* immunisation of human lymphocytes, followed by transformation of the lymphocytes with Epstein-Barr virus.

20 For the production of both monoclonal and polyclonal antibodies, the experimental animal is suitably a goat, rabbit, rat, mouse, guinea pig, chicken, sheep or horse. If desired, the immunogen may be administered as a conjugate in which the immunogen is coupled, for example via a side chain of one of the amino acid residues, to a suitable carrier. The carrier molecule is typically a physiologically acceptable carrier. The antibody obtained may be isolated and, if desired, purified.

25 Antibodies that bind to MIP-4 are known in the art and commercially available (for example, from Novus Biologicals®).

#### *Uses of MIP-4 polypeptides, polynucleotides and antibodies*

30 The invention provides a method of activating a CCRL2 signalling pathway in a cell, which method comprises introducing a MIP-4 polypeptide to a cell. The cell

may be *in vivo* or *in vitro*. The delivery of the agent is discussed in more detail below.

The invention further provides the use of:

- (i) a MIP-4 polypeptide;
- (ii) a polynucleotide that encodes a MIP-4 polypeptide; or
- (iii) an antibody specific for a MIP-4 polypeptide;

in the manufacture of a medicament for the treatment of a CCRL2-related disease or disorder. The CCRL2-related disease or disorder is preferably a CCRL2 mediated inflammatory disease such as inflammatory bowel disease, endometriosis, atherosclerosis or an inflammatory brain disorder. The inflammatory brain disorder may be multiple sclerosis, or stroke or hemorrhage. The inflammatory bowel disease may be ulcerative colitis or Crohn's disease. A CCRL2-related disease or disorder may be present, or be suspected of being present, in the individual to be treated. The individual may have a genetic predisposition to a CCRL2-related disease or disorder, such as a polymorphism.

The individual is discussed in more detail below.

#### *Uses of CCRL2 polypeptides, polynucleotides and antibodies*

The invention provides the use of:

- (i) a CCRL2 polypeptide;
- (ii) a polynucleotide that encodes a CCRL2 polypeptide; or
- (iii) an antibody specific for a CCRL2 polypeptide;

in the manufacture of a medicament for the treatment of a MIP-4-related disease or disorder. The MIP-4-related disease or disorder is preferably allergic inflammation, such as asthma or contact dermatitis. A MIP-4-related disease or disorder may be present, or be suspected of being present, in the individual to be treated. The individual may have a genetic predisposition to a MIP-4-related disease or disorder, such as a polymorphism. The individual is discussed in more detail below.

#### *Methods of diagnosis*

The invention further provides methods of diagnosing a CCRL2-related disease or disorder or an MIP-4-related disease or disorder in an individual. A

CCRL2-related disease or disorder is typically a disease or disorder which is associated with the CCRL2 gene. For example, a polymorphism in the CCRL2 gene region may be associated with the disease or disorder. A MIP-4-related disease or disorder is one which is associated with the MIP-4 gene. For example, a  
5 polymorphism in the MIP-4 gene region may be associated with the disease or disorder.

The CCRL2-related disease or disorder is preferably a CCRL2-mediated inflammatory disease such as inflammatory bowel disease endometriosis, atherosclerosis or an inflammatory brain disorder. The inflammatory brain disorder  
10 may be multiple sclerosis, or stroke or heamorrhage. The inflammatory bowel disease may be ulcerative colitis or Crohn's disease. A CCRL2-related disease or disorder may be present, or be suspected of being present, in the individual to be diagnosed. The MIP-4-related disease or disorder is preferably allergic inflammation, such as asthma or contact dermatitis. A MIP-4-related disease or  
15 disorder may be present, or be suspected of being present, in the individual to be treated. The individual is discussed in more detail below.

In a first diagnostic embodiment of the invention, the method of diagnosis comprises carrying out an amplification reaction on a sample isolated from an individual using primers specific for MIP-4. The presence or absence of a  
20 polynucleotide encoding a MIP-4 polypeptide in the sample is then determined. The absence of a polynucleotide encoding a MIP-4 polypeptide is indicative of the presence of a CCRL2-related disease or disorder. If the polynucleotide is present, the amount of the amplified polynucleotide is compared with a standard and a difference in the amount relative to the standard is indicative of the presence of a  
25 CCRL2-related disease or disorder in the individual. The standard refers to the equivalent measurement in an individual not affected by the CCRL2-related disease or disorder.

The methods of the first diagnostic embodiment also comprise carrying out an amplification reaction on a sample isolated from an individual using primers  
30 specific for CCRL2. The presence or absence of a polynucleotide encoding a CCRL2 polypeptide in the sample is then determined. The absence of a polynucleotide encoding a CCRL2 polypeptide is indicative of the presence of a

MIP-4-related disease or disorder. If the polynucleotide is present, the amount of the amplified polynucleotide is compared with a standard and a difference in the amount relative to the standard is indicative of the presence of a MIP-4-related disease or disorder in the individual. The standard refers to the equivalent measurement in an individual not affected by the MIP-4-related disease or disorder.

The amount of polynucleotide may be measured by any suitable method such as quantitative or semi-quantitative polymerase chain reaction (PCR). In these methods, part of polynucleotide in the sample is copied (or amplified) prior to determining the amount. Methods of "quantitative" amplification are well known in the art (PCR Protocols, A Guide to Methods and Applications, Innis et al., Academic Press, Inc. N.Y., (1990)).

In a second diagnostic embodiment, the method of diagnosis comprises amplifying a polynucleotide encoding MIP-4 from a sample isolated from an individual. The presence of a mutation or polymorphism associated with associated with a CCRL2-related disease or disorder is then determined. In one embodiment, the sequence of an amplified polynucleotide is compared with sequence information relating to sequences associated with CCRL2-related diseases or disorders (Figure 4). Such information typically indicates sequence polymorphisms associated with said diseases or disorders.

The methods of the second diagnostic embodiment also comprise amplifying a polynucleotide encoding CCRL2 from a sample isolated from an individual. The presence of a mutation or polymorphism associated with associated with a MIP-4-related disease or disorder is then determined. In one embodiment, the sequence of an amplified polynucleotide is compared with sequence information relating to sequences associated with MIP-4-related diseases or disorders (Figure 5). Such information typically indicates sequence polymorphisms associated with said diseases or disorders.

The mutation or polymorphism is typically detected by directly determining the presence of the mutation or polymorphism sequence in a polynucleotide of the individual. Such a polynucleotide is typically genomic DNA, mRNA or cDNA. The polymorphism may be detected by any suitable method such as those mentioned below.

The diagnostic method may comprise detecting the presence or absence of a mutation or polymorphism using a specific binding agent. A specific binding agent is an agent that binds with preferential or high affinity to the protein or polynucleotide having the polymorphism but does not bind or binds with only low affinity to other polypeptides or proteins (such as a MIP-4 polynucleotide or CCRL2 polynucleotide which does not comprise the mutation or polymorphism).

The specific binding agent may be a probe or primer. The probe may be a protein (such as an antibody) or an oligonucleotide. The probes or primers will typically also bind to flanking nucleotides and amino acids on one or both sides of the polymorphism, for example at least 2, 5, 10, 15 or more flanking nucleotide or amino acids in total or on each side. Thus a probe or primer may be fully or partially complementary to either all or part of the flanking 5' and/or 3' sequences of the mutation or polymorphism. The probe may be labelled or may be capable of being labelled indirectly. The binding of the probe to the polynucleotide or protein may be used to immobilise either the probe or the polynucleotide or protein.

Generally, determination of the specific binding of the agent to the mutation or polymorphism can be done by determining the binding of the agent to the polynucleotide of the individual. However, the agent may also be able to bind the corresponding wild-type sequence, for example by binding the nucleotides which flank the mutation or polymorphism position. In such a case, the manner of binding to the wild-type sequence will be detectably different to the binding of a polynucleotide or protein containing the polymorphism.

Oligonucleotide ligation assays involve the use of two oligonucleotide probes. These probes bind to adjacent areas on the polynucleotide which contains the mutation or polymorphism, allowing (after binding) the two probes to be ligated together by an appropriate ligase enzyme. However the presence of single mismatch within one of the probes may disrupt binding and ligation. Thus ligated probes will only occur with a polynucleotide that contains the mutation or polymorphism, and therefore the detection of the ligated product may be used to determine the presence of the mutation or polymorphism.

Probes may also be used in a heteroduplex analysis based system. In such a system when the probe is bound to polynucleotide sequence containing the mutation

or polymorphism it forms a heteroduplex at the site where the polymorphism occurs (i.e. it does not form a double strand structure). Such a heteroduplex structure can be detected by the use of single or double strand specific enzyme. Typically the probe is an RNA probe, the heteroduplex region is cleaved using RNAase H and the polymorphism is detected by detecting the cleavage products.

Mutations or polymorphisms may also be detected using fluorescent chemical cleavage mismatch analysis which is described for example in PCR Methods and Applications 3, 268-71 (1994) and Proc. Natl. Acad. Sci. 85, 4397-4401 (1998).

Alternatively, a PCR primer is used that primes a PCR reaction only if it binds a polynucleotide containing the mutation or polymorphism (i.e. a sequence- or allele-specific PCR system) and the presence of the mutation or polymorphism may be determined by the detecting the PCR product. Preferably the region of the primer which is complementary to the mutation or polymorphism is at or near the 3' end of the primer. The presence of the polymorphism may be determined using a fluorescent dye and quenching agent-based PCR assay such as the Taqman PCR detection system.

A specific binding agent may be capable of specifically binding the amino acid sequence encoded by a mutated or polymorphic sequence. For example, the agent may be an antibody or antibody fragment. The detection method may be based on an ELISA system.

The method may be an RFLP based system. This can be used if the presence of the polymorphism in the polynucleotide creates or destroys a restriction site that is recognised by a restriction enzyme.

The presence of the mutation or polymorphism may be determined based on the change which the presence of the mutation or polymorphism makes to the mobility of the polynucleotide during gel electrophoresis. In the case of a polynucleotide single-stranded conformation polymorphism (SSCP) or denaturing gradient gel electrophoresis (DDGE) analysis may be used.

In another method of detecting the mutation or polymorphism, a polynucleotide comprising the polymorphic region is sequenced across the region which contains the polymorphism to determine the presence of the polymorphism. The methods of the second diagnostic embodiment may be carried out using an



array, such as a DNA chip. For example, a probe may be immobilised on a DNA chip.

In a third diagnostic embodiment the invention, the method of diagnosis comprises contacting a sample isolated from an individual which comprises a  
5 CCRL2 peptide with a MIP-4 polypeptide under conditions which permit the binding of the MIP-4 polypeptide to the CCRL2 polypeptide. The activity of the CCRL2 polypeptide is then measured. The activity of this CCRL2 polypeptide is then compared with a standard and a difference in the activity relative to the standard indicative of the presence of a CCRL2-related disease or disorder in the individual.  
10 This standard refers to the equivalent measurement in an individual not affected by the CCRL2-relevant disease or disorder.

The methods of the third diagnostic embodiment also comprise contacting a sample isolated from an individual which comprises a MIP-4 polypeptide with a  
15 CCRL2 polypeptide under conditions which permit the binding of the MIP-4 polypeptide to the CCRL2 polypeptide. The activity of the CCRL2 polypeptide is then measured. The activity of this CCRL2 polypeptide is then compared with a standard and a difference in the activity relative to the standard indicative of the presence of a MIP-4-related disease or disorder in the individual. This standard refers to the equivalent measurement in an individual not affected by the MIP-4-  
20 relevant disease or disorder.

The conditions which permit the binding of a MIP-4 polypeptide to a CCRL2 polypeptide are, for example, the temperature, salt concentration, pH and protein concentration under which a MIP-4 polypeptide binds to a CCRL2 polypeptide. Exact binding conditions will vary depending on nature of the assay, for example,  
25 when the assay uses viable cells or only membrane fraction of cells. However, because CCLR2 is a cell surface receptor and MIP-4 polypeptides are secreted polypeptides that interact with the extracellular domain of CCRL2, preferred conditions will generally include physiological salt concentration (approx 90mM) pH about (7.0 to 8.0). Temperatures for binding may vary from 4°C through to 37°C,  
30 but is preferably 4°C. The concentration of the MIP-4 polypeptide will also vary, but will preferably be from about 0.1pM to about 10µM.

The methods of all the diagnostic embodiments are carried out *in vitro* on a

sample from the individual. The sample typically comprises a body fluid and/or cells of the individual and may, for example, be obtained using a needle and syringe or using a swab, such as a mouth swab. The sample may be a blood, urine, saliva, skin, cheek cell or hair root sample. The sample is preferably a blood sample comprising monocytes. The sample is typically processed before the method is carried out, for example DNA extraction may be carried out, the cells may be cultured or a membrane fraction may be prepared from the cells. The polynucleotide or protein in the sample may be cleaved either physically or chemically (e.g. using a suitable enzyme). In one embodiment the part of polynucleotide in the sample is copied (or amplified), e.g. by cloning or using a PCR based method prior to determining the presence of mutations or polymorphisms.

#### *Bioinformatics*

The invention provides a method for determining the presence of a MIP-4 mutation or polymorphism associated with a CCRL2-related disease or disorder or a CCRL2 mutation or polymorphism associated with a MIP-4-related disease or disorder. The sequence of a MIP-4 polynucleotide or polypeptide associated with a CCRL2-related disease or disorder may be stored in an electronic format, for example in a computer database. The sequence of a CCRL2 polynucleotide or polypeptide associated with a MIP-4-related disease or disorder may be stored in an electronic format, for example in a computer database. The database may include further information about the polynucleotides or polypeptides. For example, the database may provide one or more aspects of the following types of information: the level of association of the polynucleotide or polypeptide with a disease or disorder, the frequency of the polynucleotide or polypeptide in patients suffering from the disorder, the probability of a patient having that polynucleotide or polypeptide developing a disease or disorder, the interaction of the polynucleotide or polypeptide with a therapeutic agent.

Diagnostic methods of the invention may be carried out by electronic means, for example using a computer system. Accordingly, the present invention provides a method for diagnosing a CCRL2-related disease or disorder or determining susceptibility of an individual to a CCRL2-related disease or disorder, which method

comprises determining whether individual has a MIP-4 polynucleotide or polypeptide comprising a mutation associated with by a CCRL2-related disease or disorder by:

- 5 (i) optionally obtaining MIP-4 sequence data from a sample taken from an individual;
- (ii) inputting MIP-4 sequence data from said individual to a computer;
- (iii) comparing said data to stored MIP-4 sequence data stored in a computer database, which database comprises information relating MIP-4 sequence data to a CCRL2-related disease or disorder; and
- 10 (iv) determining on the basis of said comparison the presence or absence of a CCRL2-related disease or disorder in said individual or whether said individual is susceptible to a CCRL2-related disease or disorder.

Accordingly, the present invention also provides a method for diagnosing a MIP-4-related disease or disorder or determining susceptibility of an individual to a MIP-4-related disease or disorder, which method comprises determining whether the individual has a polynucleotide or polypeptide comprising a mutation associated with a MIP-4-related disease or disorder with by:

- (i) optionally obtaining CCRL2 sequence data from a sample taken from an individual;
- 20 (ii) inputting CCRL2 sequence data from said individual to a computer;
- (iii) comparing said data to stored CCRL2 sequence data stored in a computer database, which database comprises information relating CCRL2 sequence data to a MIP-4-related disease or disorder; and
- (iv) determining on the basis of said comparison the presence or absence of a MIP-4-related disease or disorder in said individual or whether said individual is susceptible to a MIP-4 related disease or disorder.
- 25

MIP-4 or CCRL2 sequence data may be obtained from said sample by any suitable means such as those discussed herein. The sequence of all or part of the MIP-4 or CCRL2 gene may be obtained. Standard sequencing protocols known in the art may be used to obtain sequence data.

30 The MIP-4 sequence data or the CCRL2 sequence data may be stored in a database comprising information relating to two or more mutations or

polymorphisms which are associated with a CCRL2-related disease or disorder or a MIP-4-related disease or disorder, including polymorphisms in the MIP-4 and/or CCRL2 genes and mutations or polymorphisms in genes other than the MIP-4 or CCRL2 genes.

5       The invention also provides apparatus comprising means for determining the susceptibility of an individual to a CCRL2-related disease or disorder, or a MIP-4-related disease or disorder, based on the presence of mutations or polymorphisms present in the MIP-4 gene and/or CCRL2 gene of said individual.

10       The invention further provides a computer program comprising program code means that, when executed on a computer system, instruct the computer system to perform a method of diagnosis according to the invention. Also provided is a computer program product comprising either a computer-readable storage medium having recorded thereon a computer program or program code means on a carrier wave that, when executed on a computer system, instruct the computer system to  
15       perform a method of the invention.

#### *Individual*

In all the therapeutic and diagnostic embodiments discussed above, the individual is typically a mammalian individual, for example a mammal kept as a pet  
20       or for agricultural or sporting reasons. In one embodiment the mammal is one in which CCRL2-related disease or disorder occurs naturally (without intervention by man). The mammal may be a bovine, porcine, canine, feline, rodent (such as a mouse, rat or hamster) or primate animal. In a preferred embodiment the individual is a human individual.

25

#### *Kits*

The invention provides various kits for detecting agents that modulate the activity of CCRL2. These kits comprise:

- 30       - (i) a MIP-4 polypeptide and (ii) a CCRL2 polypeptide or an isolated polynucleotide encoding a CCRL2 polypeptide;
- a MIP-4 polypeptide and a cell transformed with a polynucleotide encoding a CCRL2 polypeptide; or

- a MIP-4 polypeptide and a cell membrane fraction comprising a CCRL2 polypeptide.

The kit may additionally comprise one or more other reagents or instruments which enable any of the embodiments of the methods mentioned above to be carried out. Such reagents or instruments include one or more of the following: a means to detect the binding of the agent to the CCRL2-polypeptide, a detectable label (such as a fluorescent label), an enzyme able to act on a polynucleotide (typically a polymerase, restriction enzyme, ligase, RNase H or an enzyme which can attach a label to a polynucleotide), suitable buffer(s) (aqueous solutions) for enzyme reagents, PCR primers, a positive and/or negative control, a gel electrophoresis apparatus, a means to isolate DNA from sample, a means to obtain a sample from the individual (such as an instrument comprising a needle) or a support comprising wells on which detection reactions can be done.

#### *Yeast cells*

The invention further provides the use in a method of the invention of yeast cells transformed (or transfected) with a CCRL2 polynucleotide. Methods for the transformation (or transfection) of yeast cells are well known in the art (Davey et al., Pheromone procedures in Fission yeast, 1995, In: Microbial Gene Techniques: Methods in Molecular Genetics 6B. Adloph, K.W. San Diego: Academic Press: 247-263 and Ladds et al., Molecular Microbiology, 2003; 47(3), 781-792).

The CCRL2 polynucleotide preferably comprises the sequence of SEQ ID NO: 1 or 3 or a sequence at least 90% or 95% identical to SEQ ID NO: 1 or 3 over its entire length. CCRL2 polynucleotides can be introduced to cells using lithium acetate, electroporation or spheroplast transformation (Davey et al., Pheromone procedures in Fission yeast, 1995, In: Microbial Gene Techniques: Methods in Molecular Genetics 6B. Adloph, K.W. San Diego: Academic Press: 247-263 and Ladds et al., Molecular Microbiology, 2003; 47(3), 781-792). CCRL2 polynucleotides may also be incorporated into a recombinant vector. Preferably, a CCRL2 polynucleotide in a vector is operably linked to a control sequence which is capable of providing for the expression of the coding sequence by the host yeast cell,

i.e. the vector is an expression vector. Such expression vectors can be used to express the CCRL2 polypeptide.

The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner.

5 A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences. Multiple copies of the same or different CCRL2 polynucleotide may be introduced into the vector.

10 Such vectors may be transformed into a suitable host yeast cell to provide for expression of a CCRL2 polypeptide. Thus, a CCRL2 polypeptide can be obtained by cultivating a host yeast cell transformed or transfected with an expression vector as described above under conditions to provide for expression of the polypeptide, and recovering the expressed polypeptide. More preferably, such host cells may be used in the screening methods of the invention.

15 Any suitable vector may be used to express a CCRL2 polypeptide in the yeast cell. The vectors may be for example a plasmid vector provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable marker genes, for example *URA3*, *HIS3*, *LEU2*, *TRP1*, *LYS2* or a  
20 tetracycline resistance gene. Promoters and other expression regulation signals may be selected to be compatible with the host cell for which the expression vector is designed. Multiple copies of the same or different CCRL2 polynucleotide in a single expression vector, or more than one expression vector each including a CCRL2 polynucleotide which may be the same or different may be transformed into the host  
25 cell.

The promoter sequence is preferably a promoter sequence derived from a yeast cell and in particular *Saccharomyces cerevisiae* or *Schizosaccharomyces pombe*. Suitable promoters for the expression of the CCRL2 polynucleotide in yeast cells include *GAL*, *GAL10*, *PHO5*, *ADHI*, *PGK* and *GPD I* (Schneider and Guarente,  
30 *Methods Enzymol.*, 1991; 194: 373-388) and the thiamine repressible nmt-1 promoter (Ladds et al., *Molecular Microbiology*, 2003; 47(3), 781-792). Suitable expression vectors for the expression of the CCRL2 polynucleotide in yeast cells

include pBM150, pYEp51, pLGSD5, YEp51, pAM82, pYE4, pAAh5, pMA56, pAH9/10/21, pMA230, pMA91 and pG-1/2 (Schneider and Guarente, Methods Enzymol., 1991; 194: 373-388. The promoter or vector will be chosen to be compatible with the host yeast cell that is to be transformed.

5 Preferably, the yeast is *Saccharomyces cerevisiae* or *Schizosaccharomyces pombe*.

10 In one embodiment, the yeast cells may be G protein transplants in which at least 5, at least 10, at least 15 or at least 20 amino acids at the carboxy terminal of the yeast G $\alpha$  subunit have been replaced with the corresponding residues from a non-yeast, preferably human, G protein. Preferably, the C terminal 5 amino acids are replaced with the corresponding residues of a human G protein. Preferably, the human G protein corresponds to the G protein which the CCRL2 polypeptide naturally interacts with so that the expression of the CCRL2 polypeptide in the yeast cell results in a functional association with the transplanted G protein. The

15 functional association enables the CCRL2 polypeptide to activate the yeast cell signalling machinery. A reporter gene under the control of a promoter which is activated by the yeast cell machinery may be introduced into the yeast cell. Reporter gene expression may then be used to monitor CCRL2 activity. Suitable reporter genes include LacZ and GFP. The reporter gene may be integrated into the yeast cell

20 chromosome. The yeast cell may be derived from a *sxa2>lacZ* reporter strain (Didmon et al., Curr. Genet., 2002; 41: 241-253 and Ladds et al., Molecular Microbiology, 2003; 47(3), 781-792).

The G-protein transplant yeast cells of the invention may be used in the screening methods of the invention. Suitable non-yeast G proteins include Gpa1, Gs,

25 Gi, Go, Gq, Gz, G12, G13, G14 and G16. The G protein is preferably Gi and more preferably Gi3.

The G protein transplant cells may be generated as described in Ladds et al., Molecular Microbiology, 2003; 47(3), 781-792.

Accordingly, a preferred yeast cell provided by the invention comprises a

30 CCRL2 polypeptide, a Gi3 protein and, optionally, a reporter construct. The CCRL2 polypeptide preferably comprises the sequence show in SEQ ID NO: 2 or 4. The Gi3 protein preferably comprises 5 carboxy terminal residues from human Gi3 fused to a

yeast G protein in which the corresponding 5 carboxy terminal residues have been deleted.

*Administration or delivery*

5           When administration is for the purpose of treatment, administration may be either for prophylactic or therapeutic purpose. When provided prophylactically, the agent or polypeptide, polynucleotide or antibody is provided in advance of any symptom. The individual may have been identified as having a genetic predisposition to an inflammatory disease or disorder. For example, where the  
10       inflammatory disease or disorder is a CCRL2-related disease or disorder, such as inflammatory bowel disease, atherosclerosis, endometriosis or an inflammatory brain disease the individual may have a polymorphism in the CCRL2 gene which polymorphism is associated with the disease or disorder. The prophylactic administration of the agent or polypeptide, polynucleotide or antibody serves to  
15       prevent or attenuate any subsequent symptom. When provided therapeutically the agent or polypeptide, polynucleotide or antibody is provided at or following, preferably shortly after, the onset of a symptom. The therapeutic administration of the agent or polypeptide, polynucleotide or antibody serves to attenuate any actual symptom. Administration and therefore the methods of the invention may be carried  
20       out *in vivo* or *in vitro*.

          The formulation of any of the therapeutic agents mentioned herein, including polypeptides, polynucleotides and antibodies, will depend upon factors such as the nature of the agent and the condition to be treated. Any such agent may be administered or delivered in a variety of dosage forms. It may be administered or  
25       delivered orally (e.g. as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules), parenterally, subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion or inhalation techniques. The agent may also be administered or delivered as suppositories. A physician will be able to determine the required route of administration or delivery for each  
30       particular patient.

          Typically the agent is formulated for use with a pharmaceutically acceptable carrier or diluent. The pharmaceutical carrier or diluent may be, for example, an



isotonic solution. For example, solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tableting, sugar-coating, or film coating processes.

Liquid dispersions for oral administration may be syrups, emulsions and suspensions. The syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.

Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.

Solutions for intravenous or infusions may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.

A therapeutically effective amount of agent is administered. A therapeutically effective amount of an agent is an amount that alleviates the symptoms or which prevents or delays the onset of symptoms of an inflammatory disease or disorder.

The dose may be determined according to various parameters, especially according to the substance used; the age, weight and condition of the patient to be treated; the route of administration; and the required regimen. Again, a physician will be able to determine the required route of administration and dosage for any particular patient. A typical daily dose is from about 0.1 to 50 mg per kg, preferably

from about 0.1mg/kg to 10mg/kg of body weight, according to the activity of the specific inhibitor, the age, weight and conditions of the subject to be treated, the type and severity of the disease and the frequency and route of administration. Preferably, daily dosage levels are from 5 mg to 2 g.

5

The present invention is described with reference to the following, non-limiting Examples:

Example 1 – CCRL2 signalling assays

10

*Yeast strains*

Yeast strains were constructed as described in Ladds et al., Molecular Microbiology, 2003; 47(3), 781-792.

15

*Yeast assays*

All assays were performed by Septegen's standard protocols (Ladds et al., Molecular Microbiology, 2003; 47(3), 781-792). Yeast strains were incubated with ligand for 16 hours prior to assaying LacZ activity.

20

*CCRL2 activity in the presence of MIP-4*

MIP-4 was received from R&D Systems and stored at -20°C until use. MIP-4 was dissolved in growth medium containing 0.1% BSA to provide a stock solution of 11.1  $\mu$ M (50  $\mu$ g of chemokine in final volume of 577  $\mu$ l). For the initial screen of the G-protein transplant strains, 210  $\mu$ l of the 11.1  $\mu$ M stock was diluted to a final volume of 2.1 ml to give a working concentration of 1.11  $\mu$ M.

25

For each of the G-transplant strains, 180  $\mu$ l of 1.11  $\mu$ M solution was added to 20  $\mu$ l of cells. The final assay volume was 200  $\mu$ l and the final concentration of MIP-4 was 1  $\mu$ M. MIP-4 activated the short form of CCRL2 (CRAM-B) in Gi3 transplant strains (Figure 1).

30

On the basis of the initial screen against all of the G-transplants, MIP-4 was assayed against the Gi3-transplant at a range of concentrations. A series of 10-fold dilutions were made from the 11.1  $\mu$ M stock (30  $\mu$ l plus 270  $\mu$ l). For each sample,

180  $\mu$ l of the appropriately diluted stock was added to 20  $\mu$ l of cells (final concentrations of 10  $\mu$ M, 1  $\mu$ M etc.). The response of the Gi3 transplant cells increased exponentially with increasing concentrations of MIP-4 (Figure 2).

## 5 *Control experiments*

To confirm that the responses reported for the various chemokines are dependent upon the CCRL2 receptor, all three chemokines were assayed against appropriate yeast strains expressing the Corticotropin Releasing Factor Receptor (CRFR). This was chosen as control strain since it has peptide agonists and interacts with the Gq, Gi2 and Gi3 transplants and the interaction is dependent upon the identity of the ligand. MIP-4 was active against the short form of CCRL2 (CRAM-B) in the Gi3-transplant ( $10^{-6}$  M resulted in ~6.5 LacZ units) (Figure 3). Monocyte chemotactic protein-1 (MCP-1) was active against the short form of CCRL2 (CRAM-B) in the Gq-transplant ( $10^{-6}$  M resulted in ~5.7 LacZ units) (Figure 3). Monocyte chemotactic protein-3 (MCP-3) was active against the short form of CCRL2 (CRAM-B) in the Gi2-transplant ( $10^{-6}$  M resulted in ~2.2 LacZ units) (Figure 3).

Corticotrophin releasing factor (CRF) was active against CRF-R1 in the Gi2-transplant ( $10^{-6}$  M resulted in ~6.4 LacZ units) and the Gi3-transplant ( $10^{-6}$  M resulted in ~17.2 LacZ units) (Figure 3). Urocortin was active against CRF-R1 in the Gq-transplant ( $10^{-6}$  M resulted in ~6.9 LacZ units).

## Example 2 – CCRL2 chemotaxis assays

### 25 *Chemotaxis assay*

An 8 $\mu$ m-pore sized 96-well ChemoTx plate (Neuroprobe) was pre-coated with 10 $\mu$ g/ml fibronectin. Transfected cells were fluorescently-labeled with 5 $\mu$ g/ml calcein (Molecular Probes) for 30 min at 37°C. 25 $\mu$ l of cells at a density of  $3 \times 10^6$  cells/ml and test samples (29 $\mu$ l) prepared in appropriate media were applied to the upper and lower chambers of the ChemoTx plate. After incubation at 37°C for 5h, any cells remaining on top of the filter were removed by EDTA-treatment and the migrated cells on the underside of the filter and in the wells were quantitated in a

fluorescent plate reader (Perkin Elmer).

MIP-4 stimulated chemotaxis of cells transfected with the short form of CCRL2 (CRAM-B). MIP-4 had no effect on cells that were not transfected with the short form of CCRL2 (CRAM-B).

## SEQUENCE LISTING

&lt;110&gt; OXAGEN LIMITED

&lt;120&gt; Ligand

&lt;130&gt; N.89652 GCW

&lt;160&gt; 5

&lt;170&gt; PatentIn version 3.2

&lt;210&gt; 1

&lt;211&gt; 1531

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (48)..(1118)

&lt;400&gt; 1

aggaagctgc ttcgggggggt gagcaaactt tttaaaatgc agaaatt atg atc tac 56  
 Met Ile Tyr  
 1

acc cgt ttc tta aaa ggc agt ctg aag atg gcc aat tac acg ctg gca 104  
 Thr Arg Phe Leu Lys Gly Ser Leu Lys Met Ala Asn Tyr Thr Leu Ala  
 5 10 15

cca gag gat gaa tat gat gtc ctc ata gaa ggt gaa ctg gag agc gat 152  
 Pro Glu Asp Glu Tyr Asp Val Leu Ile Glu Gly Glu Leu Glu Ser Asp  
 20 25 30 35

gag gca gag caa tgt gac aag tat gac gcc cag gca ctc tca gcc cag 200  
 Glu Ala Glu Gln Cys Asp Lys Tyr Asp Ala Gln Ala Leu Ser Ala Gln  
 40 45 50

ctg gtg cca tca ctc tgc tct gct gtg ttt gtg atc ggt gtc ctg gac 248  
 Leu Val Pro Ser Leu Cys Ser Ala Val Phe Val Ile Gly Val Leu Asp  
 55 60 65

aat ctc ctg gtt gtg ctt atc ctg gta aaa tat aaa gga ctc aaa cgc 296  
 Asn Leu Leu Val Val Leu Ile Leu Val Lys Tyr Lys Gly Leu Lys Arg  
 70 75 80

gtg gaa aat atc tat ctt cta aac ttg gca gtt tct aac ttg tgt ttc 344  
 Val Glu Asn Ile Tyr Leu Leu Asn Leu Ala Val Ser Asn Leu Cys Phe  
 85 90 95

ttg ctt acc ctg ccc ttc tgg gct cat gct ggg ggc gat ccc atg tgt 392  
 Leu Leu Thr Leu Pro Phe Trp Ala His Ala Gly Gly Asp Pro Met Cys  
 100 105 110 115

aaa att ctc att gga ctg tac ttc gtg ggc ctg tac agt gag aca ttt 440  
 Lys Ile Leu Ile Gly Leu Tyr Phe Val Gly Leu Tyr Ser Glu Thr Phe  
 120 125 130

|   |      |
|---|------|
| ttc aat tgc ctt ctg act gtg caa agg tac cta gtg ttt ttg cac aag | 488  |
| Phe Asn Cys Leu Leu Thr Val Gln Arg Tyr Leu Val Phe Leu His Lys |      |
| 135 140 145   |      |
| ggc aac ttt ttc tca gcc agg agg agg gtg ccc tgt ggc atc att aca | 536  |
| Gly Asn Phe Phe Ser Ala Arg Arg Arg Val Pro Cys Gly Ile Ile Thr |      |
| 150 155 160   |      |
| agt gtc ctg gca tgg gta aca gcc att ctg gcc act ttg cct gaa tac | 584  |
| Ser Val Leu Ala Trp Val Thr Ala Ile Leu Ala Thr Leu Pro Glu Tyr |      |
| 165 170 175   |      |
| gtg gtt tat aaa cct cag atg gaa gac cag aaa tac aag tgt gca ttt | 632  |
| Val Val Tyr Lys Pro Gln Met Glu Asp Gln Lys Tyr Lys Cys Ala Phe |      |
| 180 185 190 195   |      |
| agc aga act ccc ttc ctg cca gct gat gag aca ttc tgg aag cat ttt | 680  |
| Ser Arg Thr Pro Phe Leu Pro Ala Asp Glu Thr Phe Trp Lys His Phe |      |
| 200 205 210   |      |
| ctg act tta aaa atg aac att tcg gtt ctt gtc ctc ccc cta ttt att | 728  |
| Leu Thr Leu Lys Met Asn Ile Ser Val Leu Val Leu Pro Leu Phe Ile |      |
| 215 220 225   |      |
| ttt aca ttt ctc tat gtg caa atg aga aaa aca cta agg ttc agg gag | 776  |
| Phe Thr Phe Leu Tyr Val Gln Met Arg Lys Thr Leu Arg Phe Arg Glu |      |
| 230 235 240   |      |
| cag agg tat agc ctt ttc aag ctt gtt ttt gcc ata atg gta gtc ttc | 824  |
| Gln Arg Tyr Ser Leu Phe Lys Leu Val Phe Ala Ile Met Val Val Phe |      |
| 245 250 255   |      |
| ctt ctg atg tgg gcg ccc tac aat att gca ttt ttc ctg tcc act ttc | 872  |
| Leu Leu Met Trp Ala Pro Tyr Asn Ile Ala Phe Phe Leu Ser Thr Phe |      |
| 260 265 270 275   |      |
| aaa gaa cac ttc tcc ctg agt gac tgc aag agc agc tac aat ctg gac | 920  |
| Lys Glu His Phe Ser Leu Ser Asp Cys Lys Ser Ser Tyr Asn Leu Asp |      |
| 280 285 290   |      |
| aaa agt gtt cac atc act aaa ctc atc gcc acc acc cac tgc tgc atc | 968  |
| Lys Ser Val His Ile Thr Lys Leu Ile Ala Thr Thr His Cys Cys Ile |      |
| 295 300 305   |      |
| aac cct ctc ctg tat gcg ttt ctt gat ggg aca ttt agc aaa tac ctc | 1016 |
| Asn Pro Leu Leu Tyr Ala Phe Leu Asp Gly Thr Phe Ser Lys Tyr Leu |      |
| 310 315 320   |      |
| tgc cgc tgt ttc cat ctg cgt agt aac acc cca ctt caa ccc agg ggg | 1064 |
| Cys Arg Cys Phe His Leu Arg Ser Asn Thr Pro Leu Gln Pro Arg Gly |      |
| 325 330 335   |      |
| cag tct gca caa ggc aca tcg agg gaa gaa cct gac cat tcc acc gaa | 1112 |
| Gln Ser Ala Gln Gly Thr Ser Arg Glu Glu Pro Asp His Ser Thr Glu |      |
| 340 345 350 355   |      |
| gtg taa actagcatcc accaaatgca agaagaataa acatggattt tcatttttct  | 1168 |
| Val   |      |

gcattatttc atgtaaattt tctacacatt tgtatacaaa atcggataca ggaagaaaag 1228  
 ggagaggtga gctaacattt gctaagcact gaatttgtct caggcacctg gcaaggctct 1288  
 ttacaaacgt gagctccttc gcctcctacc acttgtccat agtgtggata ggactagtct 1348  
 catttctctg agaagaaaac taaggcgcgg aaatttgtct aagatcacat aactaggaag 1408  
 tggcagaact gattctccag ccctggtagc atttgctcag agcctacgct tgggtccagaa 1468  
 catcaaactc caaaccttgg ggacaaacga catgaaataa atgtatttta aaacatctaa 1528  
 aaa 1531

<210> 2  
 <211> 356  
 <212> PRT  
 <213> Homo sapiens

<400> 2

Met Ile Tyr Thr Arg Phe Leu Lys Gly Ser Leu Lys Met Ala Asn Tyr  
 1 5 10 15  
 Thr Leu Ala Pro Glu Asp Glu Tyr Asp Val Leu Ile Glu Gly Glu Leu  
 20 25 30  
 Glu Ser Asp Glu Ala Glu Gln Cys Asp Lys Tyr Asp Ala Gln Ala Leu  
 35 40 45  
 Ser Ala Gln Leu Val Pro Ser Leu Cys Ser Ala Val Phe Val Ile Gly  
 50 55 60  
 Val Leu Asp Asn Leu Leu Val Val Leu Ile Leu Val Lys Tyr Lys Gly  
 65 70 75 80  
 Leu Lys Arg Val Glu Asn Ile Tyr Leu Leu Asn Leu Ala Val Ser Asn  
 85 90 95  
 Leu Cys Phe Leu Leu Thr Leu Pro Phe Trp Ala His Ala Gly Gly Asp  
 100 105 110  
 Pro Met Cys Lys Ile Leu Ile Gly Leu Tyr Phe Val Gly Leu Tyr Ser  
 115 120 125  
 Glu Thr Phe Phe Asn Cys Leu Leu Thr Val Gln Arg Tyr Leu Val Phe  
 130 135 140  
 Leu His Lys Gly Asn Phe Phe Ser Ala Arg Arg Arg Val Pro Cys Gly  
 145 150 155 160  
 Ile Ile Thr Ser Val Leu Ala Trp Val Thr Ala Ile Leu Ala Thr Leu  
 165 170 175  
 Pro Glu Tyr Val Val Tyr Lys Pro Gln Met Glu Asp Gln Lys Tyr Lys  
 180 185 190

Cys Ala Phe Ser Arg Thr Pro Phe Leu Pro Ala Asp Glu Thr Phe Trp  
 195 200 205  
 Lys His Phe Leu Thr Leu Lys Met Asn Ile Ser Val Leu Val Leu Pro  
 210 215 220  
 Leu Phe Ile Phe Thr Phe Leu Tyr Val Gln Met Arg Lys Thr Leu Arg  
 225 230 235 240  
 Phe Arg Glu Gln Arg Tyr Ser Leu Phe Lys Leu Val Phe Ala Ile Met  
 245 250 255  
 Val Val Phe Leu Leu Met Trp Ala Pro Tyr Asn Ile Ala Phe Phe Leu  
 260 265 270  
 Ser Thr Phe Lys Glu His Phe Ser Leu Ser Asp Cys Lys Ser Ser Tyr  
 275 280 285  
 Asn Leu Asp Lys Ser Val His Ile Thr Lys Leu Ile Ala Thr Thr His  
 290 295 300  
 Cys Cys Ile Asn Pro Leu Leu Tyr Ala Phe Leu Asp Gly Thr Phe Ser  
 305 310 315 320  
 Lys Tyr Leu Cys Arg Cys Phe His Leu Arg Ser Asn Thr Pro Leu Gln  
 325 330 335  
 Pro Arg Gly Gln Ser Ala Gln Gly Thr Ser Arg Glu Glu Pro Asp His  
 340 345 350  
 Ser Thr Glu Val  
 355

<210> 3  
 <211> 1771  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> CDS  
 <222> (328)..(1362)

<400> 3  
 aaaggtcaca gggaaatcaa aggcggggta cagggccaga gggaggagga aacaacttcc 60  
 cggttgcttt cagacgcttc agagatcctc tggaggcctg ggggagcttt tgagtacttt 120  
 atttcagttg gtccctgagc tcggtgagtg gggcgggtag agccaccagg ggaatcaaca 180  
 gtggtttctc gtgcccetca gggtcaggag cagtctgatic aaaaggaggg catccactgt 240  
 ccggggccat tcccacagct cccggatgct gggctctggag gctgcgccct tcccctgcag 300  
 gagctcagcc cagtgggcag tctgaag atg gcc aat tac acg ctg gca cca gag 354  
 Met Ala Asn Tyr Thr Leu Ala Pro Glu  
 1 5



|   |      |
|---|------|
| gat gaa tat gat gtc ctc ata gaa ggt gaa ctg gag agc gat gag gca<br>Asp Glu Tyr Asp Val Leu Ile Glu Gly Glu Leu Glu Ser Asp Glu Ala<br>10 15 20 25     | 402  |
| gag caa tgt gac aag tat gac gcc cag gca ctc tca gcc cag ctg gtg<br>Glu Gln Cys Asp Lys Tyr Asp Ala Gln Ala Leu Ser Ala Gln Leu Val<br>30 35 40        | 450  |
| cca tca ctc tgc tct gct gtg ttt gtg atc ggt gtc ctg gac aat ctc<br>Pro Ser Leu Cys Ser Ala Val Phe Val Ile Gly Val Leu Asp Asn Leu<br>45 50 55        | 498  |
| ctg gtt gtg ctt atc ctg gta aaa tat aaa gga ctc aaa cgc gtg gaa<br>Leu Val Val Leu Ile Leu Val Lys Tyr Lys Gly Leu Lys Arg Val Glu<br>60 65 70        | 546  |
| aat atc tat ctt cta aac ttg gca gtt tct aac ttg tgt ttc ttg ctt<br>Asn Ile Tyr Leu Leu Asn Leu Ala Val Ser Asn Leu Cys Phe Leu Leu<br>75 80 85        | 594  |
| acc ctg ccc ttc tgg gct cat gct ggg ggc gat ccc atg tgt aaa att<br>Thr Leu Pro Phe Trp Ala His Ala Gly Gly Asp Pro Met Cys Lys Ile<br>90 95 100 105   | 642  |
| ctc att gga ctg tac ttc gtg ggc ctg tac agt gag aca ttt ttc aat<br>Leu Ile Gly Leu Tyr Phe Val Gly Leu Tyr Ser Glu Thr Phe Phe Asn<br>110 115 120     | 690  |
| tgc ctt ctg act gtg caa agg tac cta gtg ttt ttg cac aag ggc aac<br>Cys Leu Leu Thr Val Gln Arg Tyr Leu Val Phe Leu His Lys Gly Asn<br>125 130 135     | 738  |
| ttt ttc tca gcc agg agg agg gtg ccc tgt ggc atc att aca agt gtc<br>Phe Phe Ser Ala Arg Arg Arg Val Pro Cys Gly Ile Ile Thr Ser Val<br>140 145 150     | 786  |
| ctg gca tgg gta aca gcc att ctg gcc act ttg cct gaa tac gtg gtt<br>Leu Ala Trp Val Thr Ala Ile Leu Ala Thr Leu Pro Glu Tyr Val Val<br>155 160 165     | 834  |
| tat aaa cct cag atg gaa gac cag aaa tac aag tgt gca ttt agc aga<br>Tyr Lys Pro Gln Met Glu Asp Gln Lys Tyr Lys Cys Ala Phe Ser Arg<br>170 175 180 185 | 882  |
| act ccc ttc ctg cca gct gat gag aca ttc tgg aag cat ttt ctg act<br>Thr Pro Phe Leu Pro Ala Asp Glu Thr Phe Trp Lys His Phe Leu Thr<br>190 195 200     | 930  |
| tta aaa atg aac att tcg gtt ctt gtc ctc ccc cta ttt att ttt aca<br>Leu Lys Met Asn Ile Ser Val Leu Val Leu Pro Leu Phe Ile Phe Thr<br>205 210 215     | 978  |
| ttt ctc tat gtg caa atg aga aaa aca cta agg ttc agg gag cag agg<br>Phe Leu Tyr Val Gln Met Arg Lys Thr Leu Arg Phe Arg Glu Gln Arg<br>220 225 230     | 1026 |
| tat agc ctt ttc aag ctt gtt ttt gcc ata atg gta gtc ttc ctt ctg<br>Tyr Ser Leu Phe Lys Leu Val Phe Ala Ile Met Val Val Phe Leu Leu<br>235 240 245     | 1074 |

atg tgg gcg ccc tac aat att gca ttt ttc ctg tcc act ttc aaa gaa 1122  
 Met Trp Ala Pro Tyr Asn Ile Ala Phe Phe Leu Ser Thr Phe Lys Glu  
 250 255 260 265

cac ttc tcc ctg agt gac tgc aag agc agc tac aat ctg gac aaa agt 1170  
 His Phe Ser Leu Ser Asp Cys Lys Ser Ser Tyr Asn Leu Asp Lys Ser  
 270 275 280

gtt cac atc act aaa ctc atc gcc acc acc cac tgc tgc atc aac cct 1218  
 Val His Ile Thr Lys Leu Ile Ala Thr Thr His Cys Cys Ile Asn Pro  
 285 290 295

ctc ctg tat gcg ttt ctt gat ggg aca ttt agc aaa tac ctc tgc cgc 1266  
 Leu Leu Tyr Ala Phe Leu Asp Gly Thr Phe Ser Lys Tyr Leu Cys Arg  
 300 305 310

tgt ttc cat ctg cgt agt aac acc cca ctt caa ccc agg ggg cag tct 1314  
 Cys Phe His Leu Arg Ser Asn Thr Pro Leu Gln Pro Arg Gly Gln Ser  
 315 320 325

gca caa ggc aca tcg agg gaa gaa cct gac cat tcc acc gaa gtg taa 1362  
 Ala Gln Gly Thr Ser Arg Glu Glu Pro Asp His Ser Thr Glu Val  
 330 335 340

actagcatcc accaaatgca agaagaataa acatggattt tcattctttct gcattatttc 1422

atgtaaattt tctacacatt tgtatacaaa atcggatata ggaagaaaag ggagaggtga 1482

gctaacattt gctaagcact gaatttgtct caggcaccgt gcaaggctct ttacaaacgt 1542

gagctccttc gcctcctacc acttgtccat agtgtggata ggactagtct caattctctg 1602

agaagaaaac taaggcgcgg aaatttgtct aagatcacat aactaggaag tggcagaact 1662

gattctccag ccctggtagc atttgctcag agcctacgct tgggtccagaa catcaaactc 1722

caaaccctgg ggacaaacga catgaaataa atgtatttta aaacatcta 1771

<210> 4

<211> 344

<212> PRT

<213> Homo sapiens

<400> 4

Met Ala Asn Tyr Thr Leu Ala Pro Glu Asp Glu Tyr Asp Val Leu Ile  
 1 5 10 15

Glu Gly Glu Leu Glu Ser Asp Glu Ala Glu Gln Cys Asp Lys Tyr Asp  
 20 25 30

Ala Gln Ala Leu Ser Ala Gln Leu Val Pro Ser Leu Cys Ser Ala Val  
 35 40 45

Phe Val Ile Gly Val Leu Asp Asn Leu Leu Val Val Leu Ile Leu Val  
 50 55 60

Lys Tyr Lys Gly Leu Lys Arg Val Glu Asn Ile Tyr Leu Leu Asn Leu  
 65 70 75 80  
 Ala Val Ser Asn Leu Cys Phe Leu Leu Thr Leu Pro Phe Trp Ala His  
 85 90 95  
 Ala Gly Gly Asp Pro Met Cys Lys Ile Leu Ile Gly Leu Tyr Phe Val  
 100 105 110  
 Gly Leu Tyr Ser Glu Thr Phe Phe Asn Cys Leu Leu Thr Val Gln Arg  
 115 120 125  
 Tyr Leu Val Phe Leu His Lys Gly Asn Phe Phe Ser Ala Arg Arg Arg  
 130 135 140  
 Val Pro Cys Gly Ile Ile Thr Ser Val Leu Ala Trp Val Thr Ala Ile  
 145 150 155 160  
 Leu Ala Thr Leu Pro Glu Tyr Val Val Tyr Lys Pro Gln Met Glu Asp  
 165 170 175  
 Gln Lys Tyr Lys Cys Ala Phe Ser Arg Thr Pro Phe Leu Pro Ala Asp  
 180 185 190  
 Glu Thr Phe Trp Lys His Phe Leu Thr Leu Lys Met Asn Ile Ser Val  
 195 200 205  
 Leu Val Leu Pro Leu Phe Ile Phe Thr Phe Leu Tyr Val Gln Met Arg  
 210 215 220  
 Lys Thr Leu Arg Phe Arg Glu Gln Arg Tyr Ser Leu Phe Lys Leu Val  
 225 230 235 240  
 Phe Ala Ile Met Val Val Phe Leu Leu Met Trp Ala Pro Tyr Asn Ile  
 245 250 255  
 Ala Phe Phe Leu Ser Thr Phe Lys Glu His Phe Ser Leu Ser Asp Cys  
 260 265 270  
 Lys Ser Ser Tyr Asn Leu Asp Lys Ser Val His Ile Thr Lys Leu Ile  
 275 280 285  
 Ala Thr Thr His Cys Cys Ile Asn Pro Leu Leu Tyr Ala Phe Leu Asp  
 290 295 300  
 Gly Thr Phe Ser Lys Tyr Leu Cys Arg Cys Phe His Leu Arg Ser Asn  
 305 310 315 320  
 Thr Pro Leu Gln Pro Arg Gly Gln Ser Ala Gln Gly Thr Ser Arg Glu  
 325 330 335  
 Glu Pro Asp His Ser Thr Glu Val  
 340

<210> 5  
 <211> 793  
 <212> DNA  
 <213> Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (61)..(330)

&lt;400&gt; 5

aggagttgtg agttttccaag cccagactca ctctgaccac ttctctgcct gccagcatc 60

atg aag ggc ctt gca gct gcc ctg ctt gtc ctg gtc tgc acc atg gcc 108  
 Met Lys Gly Leu Ala Ala Ala Leu Leu Val Leu Val Cys Thr Met Ala  
 1 5 10 15

ctc tgc tcc tgt gca caa gtt ggt acc aac aaa gag ctg tgc tgc ctg 156  
 Leu Cys Ser Cys Ala-Gln Val Gly Thr Asn Lys Glu Leu Cys Cys Leu  
 20 25 30

gtc tat acc tcc tgg cag att cca caa aag ttc ata gtt gac tat tct 204  
 Val Tyr Thr Ser Trp Gln Ile Pro Gln Lys Phe Ile Val Asp Tyr Ser  
 35 40 45

gaa acc agc ccc cag tgc ccc aag cca ggt gtc atc ctg cta acc aag 252  
 Glu Thr Ser Pro Gln Cys Pro Lys Pro Gly Val Ile Leu Leu Thr Lys  
 50 55 60

aga ggc cgg cag atc tgt gct gac ccc aat aag aag tgg gtc cag aaa 300  
 Arg Gly Arg Gln Ile Cys Ala Asp Pro Asn Lys Lys Trp Val Gln Lys  
 65 70 75 80

tac atc agc gac ctg aag ctg aat gcc tga ggggcctgga agctgcgagg 350  
 Tyr Ile Ser Asp Leu Lys Leu Asn Ala  
 85

gccagtgaa cttggtgggc ccaggaggga acaggagcct gagccagggc aatggccctg 410

ccaccctgga ggccacctct tctaagagtc ccatctgcta tgcccagcca cattaactaa 470

ctttaatctt agtttatgca tcatatttca ttttgaaatt gatttctatt gttgagctgc 530

attatgaaat tagtattttc tctgacatct catgacattg tctttatcat cctttcccct 590

ttcccttcaa ctcttcgtac attcaatgca tggatcaatc agtgtgatta gctttctcag 650

cagacattgt gccatatgta tcaaatgaca aatctttatt gaatggtttt gctcagcacc 710

accttttaaat atattggcag tacttattat ataaaaggta aaccagcatt ctactgtga 770

aaaaaaaaa aaaaaaaaaa aaa 793

&lt;210&gt; 6

&lt;211&gt; 89

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 6

Met Lys Gly Leu Ala Ala Ala Leu Leu Val Leu Val Cys Thr Met Ala  
 1 5 10 15

Leu Cys Ser Cys Ala Gln Val Gly Thr Asn Lys Glu Leu Cys Cys Leu  
20 25 30

Val Tyr Thr Ser Trp Gln Ile Pro Gln Lys Phe Ile Val Asp Tyr Ser  
35 40 45

Glu Thr Ser Pro Gln Cys Pro Lys Pro Gly Val Ile Leu Leu Thr Lys  
50 55 60

Arg Gly Arg Gln Ile Cys Ala Asp Pro Asn Lys Lys Trp Val Gln Lys  
65 70 75 80

Tyr Ile Ser Asp Leu Lys Leu Asn Ala  
85

CLAIMS

1. A method of detecting an agent that modulates the activity of CCRL2, the method comprising:

(a) contacting a CCRL2 polypeptide with a macrophage inflammatory protein-4 (MIP-4) polypeptide in the presence of a candidate agent under conditions, which in the absence of the test agent, permit the binding of the MIP-4 polypeptide to the CCRL2 polypeptide; and

(b) determining whether the candidate agent is capable of modulating the interaction between said CCRL2 polypeptide and said MIP-4 polypeptide.

2. A method according to claim 1, wherein the MIP-4 polypeptide is a polypeptide comprising:

(a) the sequence shown in SEQ ID NO: 6; or

(b) a sequence which is at least 50% identical to SEQ ID NO: 6 and which binds to and activates a signalling activity of CCRL2;

or is a fragment of SEQ ID NO: 6 which binds to and activates a signalling activity of CCRL2.

3. A method according to claim 1 or 2, wherein the CCRL2 polypeptide is a polypeptide comprising:

(a) the sequence shown in SEQ ID NO: 2 or 4;

(b) a sequence which is at least 80% identical to SEQ ID NO: 2 or 4 over its entire length and functionally equivalent to CCRL2.

(c) a fragment of SEQ ID NO: 2 or 4 which is functionally equivalent to CCRL2.

4. A method according to any one of the preceding claims, wherein the candidate agent is a polypeptide, an antibody or antigen-binding fragment thereof, a lipid, a carbohydrate, a nucleic acid or a chemical compound.

5. A method according to any one of the preceding claims, wherein step (b) comprises monitoring binding of the CCRL2 polypeptide to the MIP-4 polypeptide.

6. A method according to claim 5, wherein the binding of the CCRL2 polypeptide to the MIP-4 polypeptide is monitored using label displacement, surface plasmon resonance, fluorescence resonance energy transfer, fluorescence quenching

or fluorescence polarization.

7. A method according to any one of the preceding claims, wherein the MIP-4 polypeptide is detectably labelled.

8. A method according to claim 7, wherein the MIP-4 polypeptide is detectably labelled with a moiety is a radioisotope, a fluorophore, a quencher of fluorescence, an enzyme, an affinity tag or an epitope tag.

9. A method according to any one of claims 1 to 4, wherein step (b) comprises monitoring the signalling activity of the CCRL2 polypeptide.

10. A method according to claim 9, wherein the signalling activity is monitored by measurement of guanosine nucleotide binding, GTPase activity, adenylate cyclase activity, cyclic adenosine monophosphate (cAMP), Protein Kinase C activity, phosphatidylinositol breakdown, diacylglycerol, inositol triphosphate, intracellular calcium, MAP kinase activity or reporter gene expression.

11. A method according to claim 10, wherein the signalling activity is monitored by measuring the activity of Gi3.

12. A method according to any one of claims 1 to 4, wherein step (b) comprises monitoring the chemotactic activity of the CCRL2 polypeptide.

13. A method according to any one of the preceding claims, wherein the CCRL2 polypeptide is expressed on a cell.

14. A method according to claim 13, wherein the cell is a yeast cell.

15. A method according to claim 14, wherein the yeast cell comprises a G protein in which at least 5 amino acids at the carboxy terminal of a yeast G subunit have been replaced with the corresponding residues from a non-yeast G protein.

16. A method according to claim 15, wherein the non-yeast G-protein is Gi3.

17. A method according to any one of claims 1 to 11, wherein the CCRL2 polypeptide is present:

(a) in or on synthetic liposomes;

(b) in or on virus-induced budding membranes;

(c) in or on an artificial lipid bilayer; or

(c) in a membrane fraction from cells expressing the CCRL2 polypeptide.

18. An agent detected by a method according to any one of the preceding claims.

19. A method of modulating the activity of a CCRL2 polypeptide in a cell, the method comprising delivering an agent according to claim 18 to the cell, such that the activity of CCRL2 is modulated.

20. A method according to claim 19, wherein the cell is *in vitro*.

21. A pharmaceutical composition comprising an agent according to claim 18 and a pharmaceutically acceptable carrier or diluent.

22. A method for treating an inflammatory disease or disorder, the method comprising administering a therapeutically effective amount of an agent according to claim 18 or a pharmaceutical composition according to claim 21 to an individual in need thereof.

23. A method according to claim 22, wherein the inflammatory disease or disorder is chronic obstructive pulmonary disease (COPD), bronchitis, emphysema, an inflammatory bone disorder, psoriasis, inflammatory bowel disease, an inflammatory brain disorder, atherosclerosis, endometriosis, autoimmune deficiency syndrome (AIDS), lupus erythematosus, allograft rejection or allergic inflammation.

24. An agent according to claim 18 or a pharmaceutical composition according to claim 21 for use in a method of treatment of a human or animal body by therapy.

25. Use of an agent according to claim 18 in the manufacture of a medicament for the treatment of an inflammatory disease or disorder.

26. A use according to claim 25, wherein the inflammatory disease or disorder is chronic obstructive pulmonary disease (COPD), bronchitis, emphysema, an inflammatory bone disorder, psoriasis, inflammatory bowel disease, an inflammatory brain disorder, atherosclerosis, endometriosis, autoimmune deficiency syndrome (AIDS), lupus erythematosus, allograft rejection or allergic inflammation.

27. A method of activating a CCRL2 signalling pathway in a cell, the method comprising delivering, to the cell, a polypeptide comprising:

- (a) the MIP-4 sequence shown in SEQ ID NO: 6; or
- (b) a sequence at least 50% identical to SEQ ID NO: 6 and which binds to and activates a signalling activity of CCRL2; or



(c) a fragment of SEQ ID NO: 6 which binds to and activates a signalling activity of CCRL2.

28. A method according to claim 27, wherein the cell is *in vitro*.

29. Use of a polypeptide comprising:

(a) the MIP-4 sequence shown in SEQ ID NO: 6; or

(b) a sequence at least 50% identical to SEQ ID NO: 6 and which binds to and activates a signalling activity of CCRL2; or

(c) a fragment of SEQ ID NO: 6 which binds to and activates a signalling activity of CCRL2,

a polynucleotide encoding said polypeptide, or an antibody which binds to said polypeptide for the manufacture of a medicament for treating a CCRL2-related disease or disorder.

30. A use according to claim 29, wherein the CCRL2-related disease or disorder is inflammatory bowel disease, endometriosis, atherosclerosis or an inflammatory brain disorder.

31. Use of a polypeptide comprising:

(a) the CCRL2 sequence shown in SEQ ID NO: 2 or 4;

(b) a sequence which is at least 80% identical to SEQ ID NO: 2 or 4 over its entire length and is functionally equivalent to CCRL2; or

(c) a fragment of SEQ ID NO: 2 or 4 which is functionally equivalent to CCRL2,  
a polynucleotide encoding said polypeptide, or an antibody which binds to said polypeptide for the manufacture of a medicament for treating a MIP-4-related disease or disorder.

32. A use according to claim 31, wherein the MIP-4-related disease or disorder is allergic inflammation.

33. A method of diagnosing a CCRL2-related disease or disorder in an individual, the method comprising:

(a) carrying out an amplification reaction on a sample isolated from the individual using primers specific for a polynucleotide encoding a MIP-4 polypeptide; and

(b) determining the presence or absence of a polynucleotide encoding a

MIP-4 polypeptide in the sample and thereby determining the presence of a CCRL2-related disease or disorder in the individual.

34. A method according to claim 33, further comprising comparing the amount of the amplified polynucleotide encoding a MIP-4 polypeptide produced in step (a) with a standard, wherein a difference in the amount relative to the standard is indicative of the presence of a CCRL2-related disease or disorder in the individual.

35. A method of diagnosing a CCRL2-related disease or disorder in an individual, the method comprising:

(a) amplifying a polynucleotide encoding a MIP-4 polypeptide, using a nucleic acid isolated from the individual as a template; and

(b) determining whether the polynucleotide comprises a polymorphism associated with a CCRL2-related disease or disorder.

36. A method according to claim 35, wherein step (b) comprises:

(a) inputting MIP-4 sequence data from the individual to a computer system;

(b) comparing said sequence data to a computer database, which database comprises information relating MIP-4 sequence data to a CCRL2-related disease or disorder; and

(c) determining on the basis of said comparison whether the MIP-4 polynucleotide comprises a polymorphism associated with a CCRL2-related disease or disorder.

37. A method of diagnosing a CCRL2-related disease or disorder in an individual, the method comprising:

(a) contacting a sample isolated from the individual comprising a CCRL2 polypeptide with a MIP-4 polypeptide under conditions which permit the binding of the MIP-4 polypeptide to the CCRL2 polypeptide;

(b) measuring the activity of the CCRL2 polypeptide; and

(c) comparing the activity of the CCRL2 polypeptide with a standard, wherein a difference in the activity relative to the standard is indicative of the presence of a CCRL2-related disease or disorder in the individual.

38. A method according to claim 37, wherein step (b) comprises monitoring:

- (i) the signalling activity of the CCRL2 polypeptide; or
- (ii) the chemotactic activity of the CCRL2 polypeptide.

39. A method according to any one of claims 33 to 38, wherein the MIP-4 polypeptide is a polypeptide comprising:

- (a) the sequence shown in SEQ ID NO: 6; or
- (b) a sequence at least 50% identical to SEQ ID NO: 6 and which binds to and activates a signalling activity of CCRL2; or
- (c) a fragment of SEQ ID NO: 6 which binds to and activates a signalling activity of CCRL2.

40. A method according to any one of claims 33 to 38 wherein the CCRL2-related disease or disorder is inflammatory bowel disease, endometriosis, atherosclerosis or an inflammatory brain disorder.

41. A kit for detecting an agent that modulates the activity of CCRL2, the kit comprising: (i) a MIP-4 polypeptide; and (ii) a CCRL2 polypeptide or a polynucleotide encoding a CCRL2 polypeptide.

42. A kit according to claim 41, which comprises a cell transformed with a polynucleotide encoding a CCRL2 polypeptide.

43. A kit according to claim 41, wherein the CCRL2 polypeptide is present in a cell membrane fraction, a synthetic liposome or a virus-induced budding membrane.

44. A kit according to any one of claims 41 to 43, wherein the MIP-4 polypeptide is a polypeptide comprising:

- (a) the sequence shown in SEQ ID NO: 6; or
- (b) a sequence at least 50% identical to SEQ ID NO: 6 and which binds to and activates a signalling activity of CCRL2; or
- (c) a fragment of SEQ ID NO: 6 which binds to and activates a signalling activity of CCRL2.

**ABSTRACT****LIGAND**

5       A method of detecting an agent that modulates the activity of CCRL2, the method comprising:

      (a)       contacting a CCRL2 polypeptide with a macrophage inflammatory protein-4 (MIP-4) polypeptide in the presence of a candidate agent under conditions, which in the absence of the test agent, permit the binding of the MIP-4 polypeptide  
10       to the CCRL2 polypeptide; and

      (b)       determining whether the candidate agent is capable of modulating the interaction between said CCRL2 polypeptide and said MIP-4 polypeptide.

Figure 1




Figure 2




Figure 3




Figure 4





Figure 5



**PCT/GB2004/005057**





**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☒ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**